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Abstract 
Introduction and Background 
Hepatocellular carcinoma (HCC) is one of the most common malignancies in 
the world. It develops from transformed hepatocytes during the course of 
chronic liver diseases. When transformed hepatocytes expand in vivo, they 
encounter various microenvironmental stresses which activate apoptosis and 
eventually lead to cell growth without control. Zinc finger binding protein 
-89 (ZBP-89) is a Kruppel-type transcription factor that appears to induce 
apoptosis in cancer cells. Studies have revealed that ZBP-89 possesses 
multiple functions, including transcriptional regulation of a variety of genes, 
cell growth arrest and cell death. Previous experiments have show that 
ZBP-89 can be co-localized with p53 in HCC and that the apoptosis induced 
by ZBP-89 may be associated with abnormal expression of Bcl-2 family 
members. However, the signal transductory pathway of ZBP-89-mediated 
apoptosis in HCC is unknown. Considering that ZBP-89 has ability to 
stimulate the apoptosis, understanding how ZBP-89 induces cell death in 
HCC may provide a new tool against HCC which is frequently resistant to 
currently available chemotherapy. 
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Objectives 
The purpose of this study is to investigate how ZBP-89 affects cell death of 
HCC cells through the regulation of proapoptotic member of Bcl-2 family, 
Bak. 
Methods 
Adenovirus ZBP-89 in the concentration of MOI 100 was used to infect 3 
human HCC cell lines with different p53 status: Hep3B with a deleted p53, 
SK-Hep-1 with a wild type p53 and PLC/PRF/5 with a mutated p53. The 
normal Chang liver cells which contain native p53 was also used. Protein and 
RNA levels of ZBP-89 and Bcl-2 family members were assessed by Western 
blot analyses and RT-PCR. ZBP-89-induced apoptosis was confirmed by 
TUNEL assay using flow cytometry and detection of cytochrome c release 
from mitochondria to cytosol in all tested HCC cells. ZBP-89 knockdown 
was achieved by specific short interfering siRNA. 10 various Bak pGL-3 
luciferase promoter plasmids carrying sequential 5' deletions of the Bak 
promoter region were stably transfected into four cell lines. Luciferase 
reporter assay and electrophoretic mobility shift assay (EMSA) were then 
performed to examine the binding of ZBP-89 to the Bak promoters. 
Results 
Investigated by Western blot analysis and RT-PCR, a comparatively low 
level of Bak protein and mRNA were observed in Hep3B cells among the 
other hepatoma cells. After the infection of adenovirus, protein and mRNA 
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levels of ZBP-89, Bak and cytochrome c were enhanced in all types of p53 
cells. This suggested the elevation of Bak and cytochrome c by ZBP-89 are 
not dependent on the p53 status in the cells. The blockage of ZBP-89 by 
siRNA leads to a reduction of Bak expression in all HCC cells, confirming 
that Bak is positively regulated by ZBP-89, although Hep3B with deleted p53 
is least sensitive to cell death induced by ZBP-89. A weak Bcl-2 expression 
was also observed in the HCC cells. Its protein level determined to be 
increase while ZBP-89 is silenced by siRNA, indicating the endogenous 
ZBP-89 is important in maintaining the basal level of Bcl-2 in cells. MTT 
assay was performed to determine the viable cells for 0 to 72 hours after 
treatment with or without Ad-ZBP-89. The cell died as the time of 
transfection prolonged, showing a time-dependent and reverse relationship 
between ZBP-89 and the survival of the HCC cells. However, there was no 
detectable Bax expression in all types of cells transfected with ZBP-89. The 
findings suggest that the increase of Bak rather than Bax may contribute to 
ZBP89-induced cell death. 
To examine the role of Bak in the HCC cells, overexpession of Bak using a 
pcDNA3.1-Bak plasmid transfection was employed. Western blot analysis 
revealed that the expression of Bak was in a time-dependent manner for all 
tested HCC cell lines. The level of Bak also showed greatly increase in the 
combined effect of pcDNA-Bak and Ad-ZBP-89. A TUNEL assay was 
performed to determine the overexpression of Bak was able to induce 
apoptosis in the cells. MTT assay showed that overexpression of Bak 
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significantly reduced the viability of all HCC cells. In general, the response 
of PLC/PRF/5 and SK-Hep-1 cells on up-regulating Bak expression though 
ZBP-89 infection were stronger than Hep3B cells, confirming the role of 
ZBP-89 in apoptosis of HCC cells may related to regulation of Bak, instead 
of p53 dependent. 
The lucifease reporter activity was then used to show that ZBP-89 may act on 
Bak promoter fragment between -457 and -407bp upstream of the AUG Bak 
start codon. In addition, EMSA revealed that ZBP-89 could shift the 
particular promoter fragment suggesting that possible ZBP-89-response 
element is located within this region. 
Conclusion 
ZBP-89 inhibits the proliferation of Hep3B, PLC/PRF/5 and SK-Hep-1 HCC 
cells via induction of apoptosis and ZBP-89 can significantly increase the 
level of Bak, probably via interacting with Bak promoter within -457 and 
-407bp upstream of the AUG Bak start codon. The effect of 
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1.1 Background of Hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is one of the most frequent causes of 
cancer death worldwide with a very high mortality which estimated to cause 
approximately half a million deaths annually. It is especially prevalent in 
parts of Asia and Africa, and with increasing incidence in Western countries 
which occurs mainly in patients with liver cirrhosis (Niederau et al; 1995). 
In most circumstances, HCC develops from transformed hepatocytes during 
the course of chronic liver diseases, such as hepatitis B viral (HBV) 
infection, hepatitis C viral (HCV) infection, or both (Idilma et al; 1998). 
Other risk factors include excessive alcohol consumption, drugs and 
chemicals. Obesity, diabetes (Regimbeau et al, 2004) and hypothyroidism 
(Reddy et al, 2007) can also be one of the causes of developing HCC. HCC 
is often resistant to multiple treatment modalities such as surgical therapy, 
chemotherapy and radiation. Neither single agent nor combination 
chemotherapy has demonstrated a clear reproducible advantage in terms of 
overall survival (Bruix J, Llovet JM; 2002). The survival rates of patients 
depend primarily on the stage of the tumor at diagnosis. Curative surgical 
treatment, such as local resection, ablation and liver transplantation are now 
available for early stage HCC. However, as HCC is most often diagnosed at 
advanced stages, about 70% of patients will die from recurrent tumor within 
5 years after liver tumor resection and a recurrence rate of approximately 
50% after 2 years (Llovet JM, et al; 2003). Systemic chemotherapy does not 
significantly improve survival (Bruix J, Sherman M; 2005) since the 
mechanism responsible is not well understood. Active medical strategies are 
still lacking and HCC remains one of the most difficult tumors to treat 
especially when the tumor is advanced or unresectable. Therefore, it is 
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necessary to develop and search for novel treatment modalities for HCC. 
1.2.1 ZBP-89 structure and its expression in cancers 
ZBP-89 (also as know as ZNF-148, BRCOLl and BERF-1), ubiquitously 
expressed (Wang Y, et al，1993，Law GL, et al, 1998，Reizis B et al, 1999) is 
a member of the Kruppel-type zinc finger transcription factor family that 
also includes Egrl, GATAl, Spl and WTl (Merchant et al; 2003). It 
composed of 794 residues and was cloned by the screening of an expression 
library with a GC-rich epidermal growth responsive element from the 
gastrin promoter (Merchant JL et al; 1996). The four Kruppel-type zinc 
fingers reside within the N-terminus of the protein. In addition to its 
proximal zinc-finger domain, there is a glutamic acid-rich domain within the 
first 100 residues of the protein that is followed by basic domains that flank 
the zinc-finger DNA-binding region. The distal 250 residues consist of a 
third basic domain plus serine-rich and PEST (praline, glutamic acid, serine, 
threonine) domains, which suggests that ZBP-89 might undergo proteolytic 
degradation or processing. Another member of the ZBP family was cloned 
and designated ZBP-99 on the basis of a homologous zinc-finger domain 
with a greater molecular weight. Thus, the ZBP proteins are a family of 
N-terminal zinc-finger transcriptional regulator, which is in contrast to the 
Spl family, whose zinc-finger domain resides in the extreme C-terminus of 




AD BD ZFs BD BD SD PEST 
p300 p53 transact!vation domain 
Fig.l Structure of zinc-finger binding protein (ZBP-89). The structural 
domains of ZBP-89 include the AD, acidic domain (amino acids 54-99)，BD, 
basic domains (amino acids 129-153，313-335 and 470-485)，four C2H2 zinc 
finger domain (ZFs) coloured in red (amino acids 173-278), a serine-rich 
domain, SD, (amino acids 569-596) and a PEST domain (praline, glutamic 
acid, serine and threonine). The C-terminus of ZBP-89 contains a 
transactivation domain. Proteins-protein interaction domains are indicated 
by lines and the name of the protein interacting with that domain. Domains 
that interact with p53 and p300 are indicated (Merchant et al; 2003). 
Immunohistochemical staining of human cancers revealed that ZBP-89 
protein expression is elevated (Taniuchi T, Moitensen ER et al; 1997). 
However in the APCmin mouse, ZBP-89 protein expression was lower in 
the intestinal adenomas than in the surrounding normal intestine (Bai.L, 
Logsdon, Craig et al; 2002). Moreover, higher expression of ZBP-89 was 
observed in the villus tips where the rate of apoptosis is highest (Traber PG, 
Silberg DG; 1996). In normal human stomach and colon, ZBP-89 protein is 
detected in only a few scattered cells and the expression is primarily 
cytoplasmic. The corresponding gastric and colon carcinomas show mixed 
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nuclear and cytoplasmic immunostaining (Okada M and Merchant JL), 
therefore, the subcellular location of ZBP-89 may differ according to cell 
origin. 
1.2.2 Transcriptional regulation of ZBP-89 
A GC- rich region of the human gastrin promoter was the first ZBP-89 
binding site identified (Merchant et al; 2003). ZBP-89 binding sites have 
now been identified in 11 other genes, including the mouse type I collagen 
(Hasegawa et al; 1997), rat p-enolase (Passantino et at; 1998). Human 
ornithine decarboxylase (ODC) (Law et al; 1998), human stromelysin (Ye et 
at; 1999)，human vimentin (Wieczorek et al; 2000)，the human P-2-integrin 
CD l i b gene (Park et at; 2003)，the mouse cytochrome c oxidase Vb gene 
(Boopathi et al; 2004)，etc. Studies have revealed that ZBP-89 possesses 
multiple functions, including transcriptional regulation of a variety of genes 
(Merchant JL et al; 1996，Ye S et al; 1999, Wang Y et al, 1993), cell growth 
arrest (Perrine, SP et al; 1990, Archer SY et al; 1998) and cell death (Perrine, 
SP et al; 1990). ZBP-89 has bifunctional regulatory domains, which 
suggests that it may function as a transcriptional activator and repressor 
(Hasegawa T et al; 1997，Passantino R et al; 1998). For instance, it activates 
the expression of genes such as cyclin-dependent inhibitor p21 (Bai & 
Mechant 2000, Bai et al; 2006)，growth hormone receptor lA (Xu et al; 
2006), Intestinal alkaline phosphatase gene (Malo et al; 2006), 
lymphocyte-specific protein tyrosine kinase (Yamada et al; 2001) and matrix 
metalloproteinase-3 (Borghaei et al; 2004). On the other hand, ZBP-89 m ay 
act as a repressor for gastrin, ODC, P-enolase，P-2-integrin CDl lb and 
vimentin genes. 
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The mechanism by which ZBP-89 represses transcription is relatively well 
studied. ZBP-89 can directly inhibit transcription, as in the cases of gastrin 
and P-enolase genes, or indirectly inhibit transcription through competition 
with Spl for binding to overlapping binding site, as in the case of ODC gene, 
or though blocking the activity of Spl by protein-protein interaction, as in 
the case of vimenin gene. Much less is known about how ZBP-89 activates 
transcription. In one study, ZBP-89 was shown to activate the human 
promoter through cooperation with the transcriptional co-activator p300 
(Bai & Merchant; 2000). p300 is known for its ability to connect 
sequence-specific binding proteins to the basal transcriptional machinery 
(Chan & La Thangue; 2001). There are also reports showing that ZBP-89 
inhibits the proliferation of gastric adenocarcinoma and colorectal cancer 
cells by inducing apoptosis. The anti-tumor effect of ZBP-89 has been 
further confirmed in a ZBP-89 transgenic mice experiment showing that the 
incidence of intestinal adenoma is reduced by 50% in the mice with ZBP-89 
over-expression and that correlated with increased caspase-3 level and DNA 
fragmentation (Law et al; 2006). 
1.3.1 Apoptosis and necrosis 
There are two different processes of cell deaths: apoptosis and necrosis. 
Apoptosis is a highly regulated form of programmed cell death which is 
important for elimination of redundant, damaged and viral infected cells 
(Booy et al, 2005; Ferri and Kroemer 2001; Hashemi and Kroczak, 2005). 
Necrosis is a form of traumatic cell death that results from acute cellular 
injuries. In a cell, apoptosis and necrosis may occur independently or they 
may occur at the same time (Johar et al, 2004). 
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Apoptosis is ATP-dependent and does not stimulate immune response 
(Lauber et al, 2004). It is characterized by DNA condensation and 
fragmentation, plasma membrane blobbing, and cell shrinkage. In the end, 
the cell breaks into small membrane- surrounded fragments that are cleared 
by macrophages and neighbour cells (Philchenkov et al, 2004; Reed, 2000). 
In contrast, necrosis results from metabolic disruption and energy depletion, 
mitochondrial and cellular swelling, and activation of enzymes that degrade 
cellular structures. As a result, the cell is lysed and its content is released 
into the surrounding environment. So, necrosis causes inflammation because 
of immune system effector cell recruitment (Ghavami et al, 2005). 
1.3.2 Mechanisms of Apoptosis 
Apoptosis occurs through activation of cell death machinery via specific 
molecular pathways that are under the tight control of a complex network of 
proteins and their endogenous inhibitors. Although apoptosis can be 
triggered by wide variety of insults, such as cytokines (Thorbum, 2007; 
Wang and El-Deiry, 2003), viruses (Huang et al, 2007; Liang et al, 2007) 
and anticancer drugs (Los et al, 2003)，apoptotic signalling within the cell is 
transacted mainly via two defined molecular pathways. These include the 
death receptor pathway (extrinsic pathway) and the mitochondrial pathway 
(intrinsic pathway). The end point of both the intrinsic and extrinsic 
pathways is activation of a wide variety of intracellular proteases (a group of 
proteolytic enzymes called caspases) and endonucleases that ultimately 
degrade the cellular constituents. The extrinsic and intrinsic pathways are 
not mutually exclusive, as some cells, including hepatocytes and 
cholangiocytes, have been shown to require mitochondrial involvement to 
7 
amplify the apoptotic signal from death receptors. 
The extrinsic pathway originates at the plasma membrane following the 
engagement of a family of cytokine receptors named death receptors (such 
as tumour necrosis factor (TNF) receptor, Fas/CD95, and TRAIL receptor 
by their cognate ligands. Ligands/ receptor binding induces the recruitment 
of several adapter proteins and proenzymes (that is, procaspase-8 and -10) 
and then they cleave and activate the effector caspases such as caspase 3 and 
caspase 7. This pathway is regulated by c-FLIP which inhibits the upstream 
activator caspases and lAPs (Reed, 2000; Los et al, 1995). 
Ceil-extrinsicpathway ；if, ^u/Pwpopicniiiiginci 
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Fig. 1.2 Death receptor mediated (extrinsic) apoptosis pathway. 8 
The intrinsic pathway (Fig. 1.3) is triggered by various extra- or intracellular 
signals, such as ultraviolet (UV), irradiations, oxidative stress with 
production of reactive oxygen species (ROS), toxins, reactive intermediates 
of xenobiotic metabolism, endoplasmic reticulum stress inducing factors, 
growth factor deprivation or some chemotherapeutic drugs via activation of 
proapoptotic members of the Bcl-2 family of protein (Bak, Bax), which 
oligomerise on the outer mitochondrial membrane and cause mitochondrial 
dysfunction. As a result, organelle architecture and membrane permeability 
are altered and mitochondrial proteins are released into the cytosol, 
including pro-apoptotic mitochondrial proteins such as cytochrome c, 
Smac/DLABLO, HtrA2/Omi，which contribute to protease activation and 
chromatin degradation. The cytochrome c released then activates caspase 9 
and initiates the apoptotic caspase cascade. On the other hand, 
Smac/DIABLO and HtrA2 bind and antagonize the inhibitor of apoptotic 
proteins (lAPs) (Wang, 2001; Suzuki et al, 2001). The mitochondrial 
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Fig. 1.3 Mitochondria mediated (instrinsic) apoptosis pathway. 
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1.4 Bcl-2 family 
Several intracellular proteins are involved in the regulation of apoptosis. In 
particular, the Bcl-2 family of protein, which includes both pro- and 
antiapoptotic members, are perhaps the most important regulators of the 
intrinsic pathway. These proteins act upstream and at the level of the 
mitochondria to integrate death and survival signals, and the balance 
between pro- and antiapoptotic members of the family determines whether 
or not the intrinsic pathway of apoptosis is initiated. To date, the mammalian 
Bcl-2 family comprises at least 20 members with various degrees of 
homology within four conserved regions, named Bcl-2 homology (BH) 1-4 
domains (Cory S, Adams JM et al; 2002，Cory S，Huang DC et al 2003). 
The family can be further divided into three main subclasses, defined in part 
by this homology and in part by their function. The first subclass includes 
the antiapoptotic proteins Bcl-2, Bcl-xL and Mcl-l. Their localisation is 
generally mitochondrial but some have also been found on the endoplasmic 
reticulum and nuclear membrane. They have been found to directly bind to 
several proapoptotic members of the family, however, the mechanisms by 
which they prevent mitochondrial dysfunction are still largely unclear. The 
second and third subclasses include only proapoptotic proteins called 
multi-domain Bax like protein, such as Bax and Bak，and the BH3 only 
proteins, such as Bid, Bad, Bim, Noxa and Puma. Both subclasses are 
required for apoptosis. Bax is found in cytosol as a monomer in healthy cells, 
but following an apoptotic stimulus it undergoes conformation changes, 
integrates into other mitochondrial membrane, and oligomerises, causing 
membrane permeabilisation (Hsu et al. 1997; Wolter et al. 1997; Antonsson 
et al.2001; Mikhailov et al, 1997). Bak is an oligomeric integral 
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mitochondrial membrane protein but it also undergoes conformational 
changes during apoptosis and forms larger aggregates (Nechushtan A, Smith 
CL et al; 2001，Wei MC, Lindsten T et al; 2002) Activation of either Bax or 
Bak triggers mitochondrial dysfunction and is required for apoptosis, but the 
mechanism through which mitochondrial permeabilisation is still debated. 
(Wei MC, Zong WX et al; 2001) 
1.5 Regulation of p53 cancer cells 
Among the most common alterations frequently observed in HCC, as well in 
numerous other tumours, are mutations of p53 (Harris CC, Hollstein M. et al, 
1993, Hollstein M, Sidransky D et al, 1991). The protein p53 is the product 
of a tumour suppressor gene activated as a result of DNA damage. To allow 
the repair of the DNA damage, p53 initially induces cell cycle arrest. 
However, if the damage is too extensive to be repaired and the cell has to be 
removed, p53 can also induce apoptosis by transcriptional up-regulation of 
BH3 only proteins such as Noxa, Puma and Bid, and /or the mutlidomain 
protein Bax. In addition, a transcriptional independent mechanism for p53 
medicated apoptosis has been described where it directly associates with and 
causes mitochondrial dysfunction (Mihara M, Erster S et al; 2003) Therefore, 
p53 provide an effective mechanism to protect the organism from the 
accumulation and propagation of genetic lesions. A dysfunctional p53 
allows the tumour cell to escape apoptosis and results in cancer development. 
In addition, as several chemotherapeutic drugs induce apoptosis of tumour 
cells by casing DNA damage and activation of p53, tumours with disrupted 
p53 are generally resistant to chemotherapy and associated with an 
unfavourable prognosis. Studies in vitro and in vivo have demonstrated that 
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adenoviral mediated expression of wild-type p53 suppresses the transformed 
phenotype of many cell types (Horowitz J et al; 1999, Makower D et al; 
2003) and potentiates the cytotoxicity of both chemotherapeutic agents and 
radiation therapy. However, only preliminary and not conclusive results are 
available to date from p53 gene therapy clinical trials for HCC (Ruiz J, 
Mazzolini G, et al; 2001). 
The mammalian p53 tumor suppressor protein serves as a critical 
coordinator of cellular responses to a wide variety of intrinsic and external 
stress signals (Oren; 2003, Levine et al; 2006, Vousden & Lane; 2007). Cells 
usually respond to DNA damage by activating cell cycle checkpoints and 
repair mechanisms. However, if the damage is beyond repair, the cells are 
directed towards the apoptotic pathway. Previously, the p53 dependent 
pathway was thought to be the main link between DNA damage and the 
control of apoptosis (N. Gopalakrishna Iyer et al; 2004), but more recently 
phosphorylated Bid found in an ATM-dependent manner after DNA damage 
(I Kamer，R Sarigmet al; 2005)，which suggests a possible pathway that 
links Bid to the control of apoptosis within the cell cycle arrest following 
DNA damage (Bantel H, Lugering A et al; 2004). Differential levels and 
functions of several Bcl-2 family members (like Bax and Bak) in HCC are 
known to have an anti-cancer stimulus effect (Lauber K, Bohn E, 2003) Bid 
was showed to cause a significant increase in Bax and Bak in HCC cells 
treated by etoposide and induced DNA damage, leading to the release of 
cytochrome c and the occurrence of apoptosis. In 2003，Ruffolo SC et al. 
have also showed that Bid activates Bax and Bak, both of which trigger 
apoptosis. 
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1.6 The aim of the study 
Cell proliferation and apoptosis in liver cancer cells are closely related 
phenomenon. Published reports indicated that ZBP-89 is able to both 
stimulate and repress gene expression (Wang Y et al; 1993，Law, GL et al; 
1998) in the control of cell proliferation and growth, yet the overall effect of 
ectopic ZBP-89 expression is growth suppression (Remington MC et al; 
1997). ZBP-89 may influence the cell growth through a p53-dependent or 
independent mechanism (Bai & Merchant 2001; Chen et al; 2003). They 
demonstrated that ZBP-89 stabilizes p53 via its DNA binding and 
C-terminal domains. Few studies to date have focused on the correlation 
between genes related to pro-apoptosis, such as Bak and HCC and their in 
vivo development. In the present study, we investigated the 
anti-proliferation / apoptosis effect of the transcription protein ZBP-89, 
which is adenovirus-mediated in our experiment, on HCC cells. Since p53 
mutation is a frequent event in HCC and it may also affect the transcription 
effect of ZBP-89, we therefore used HCC cells with three different p53 
statuses (wild-type, mutant and deleted p53 gene) and assessed how these 
p53 mutants would influence the ZBP-89-inducing apoptosis though the 
regulation of Bak. It is widely believed that whether ZBP-89-binding 
stimulates or inhibits gene transcription is dependent on the sequence 
content of the Bak binding site. This is why we focus on the mechanism of 
how ZBP-89 bind to the Bak promoter enhances promoter activity, and the 
underneath inhibitory mechanism of ZBP-89 in HCC remains an intriguing 
subject of future study. 
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Chapter Two 
Up-Regulation of Bak expression by ZBP-89 induces 
apoptosis in human liver cancer cells 
15 
2.1. Introduction 
Heptaocellular carcinoma (HCC), one of the most common cancers in the 
world, develops from transformed hepatocytes during the course of chronic 
liver diseases (El-Serag HB, Mason AC et al; 1999 and Ozturk M; 1995). 
When transformed hepatocytes expand in vivo they encounter various 
microenvironmental stresses, such as hypoxia, decreased growth factor, and 
lack of nutrient supply, which activate apoptosis (Evan G, Littlewood TA; 
1998). Apoptosis is the programmed cell death in which the cell actively 
uses a genetically controlled mechanism to eliminates unwanted or 
potentially harmful cells in order to maintain ontogenesis, morphogenesis, 
and homeostasis. Failure of apoptosis is now understood to contribute to the 
development of human malignancies (Friess H et al; 1998，Deng LY et al; 
1999，Zhao AG et at; 2000). Since apoptosis is a key mechanism causing 
cell death, transcription of the p53 gene can regulate progression of 
apoptosis in a wide variety of tissues. 
Since ZBP-89 has been proved to stabilizes wild type p53 and induce 
apoptosis independent of p53 or dependent of p53 (Bai et al; 1998)，there 
are an increasing studies demonstrating on how ZBP-89 initiates the cell 
growth arrest in different cancer cells by inducing apoptosis via sensitizing 
p53 gene to the anti-tumor agent or activating Bcl-2 family mediated p53 
independent but kinase-related pathway. ZBP-89 is a widely expressed 
Knippel-type zinc finger transcription factor that binds to GC-rich elements 
and function as either a transcriptional activator or repressor depending on 
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the target promoter. It is also participates in the control of cell proliferation 
and growth. In this study, three categories of human hepatocytes have been 
used to show the initiation of apoptosis after treatment with ZBP-89-bearing 
adenovirus. Chang liver cells are derived from normal liver tissue and 
express native p53, whereas hepatocellular carcinoma (HCC)-derived cell 
lines are Hep3B (p53 deleted), PLC/PRF/5 (p53 mutant) and SK-Hep-1 (p53 
normal). These cells were infected with increasing multiplicity of infection 
(MOI) and RT-PCR and Western blotting were used to detect cellular Bcl-2 
family and the expression of other-related genes. RNA interference was also 
performed by transfecting siRNA to specifically knock-down ZBP-89 
expression in HCC cells. Cell growth activities and induction of apoptosis 
after transfection with ZBP-89 and siRNA were measured by MTT assay 
and flow cytometry, respectively. ‘ 
The Bcl-2 family is the best characterized group of apoptosis mediating 
factors, which include Bak, Bax, Bcl-2, Mcl-l and several others. Although 
its members share close structural homologies, their biologic functions 
differentiate into apoptosis promoting (Bax, Bak, bcl-xS) or apoptosis 
inhibiting (Bcl-2, Mcl-l, Bcl-xL) properties (Press H et al; 1998). The Bcl-2 
related genes regulate cell death and are considered to correlate with the 
pathogenesis and progression of cancers (Xiao B et al; 1998, Yuan RW et at; 
1999，Chen XJ et al; 2000). Since Bcl-2 family members are involved in the 
pathogenesis or the treatment of HCC and the relationship between Bcl-2 
family and ZBP-89 in HCC is still unclear, we investigated the expression of 
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Bak and Bcl-2 in HCC and normal control cells treated by ZBP-89 to study 
the relationship between the Bcl-2 family members and ZBP-89 in HCC 
cells. 
2.2. Materials and methods 
2.2.1. Cell culture. 
Three human liver cancer cell lines (Hep3B, PLC/PRF/5, SK-Hep-1) and a 
normal human liver cell line (Chang Liver) were purchased from the 
American Type Culture Collection (ATCC, Rockville, MD). 
Histopathologically, Hep3B is the human HCC cell line which contains a 
major deletion of wild-type p53 gene (a 7-kb DNA fragment distal to exon 7 
of p53 gene was deleted) (Lin et al; 1996)，resulting in the lack of p53 
expression. PCIVPRF/S is the HCC with a non-functioning mutant p53 at 
codon 220 (Hsu et al; 1993). SK-Hep-1 contains wild type p53 (Puisieux et 
al; 1995). Chang Liver cells have native functional p53 and they were used 
as control. All of the cell lines were grown in 100mm tissue culture dish 
(Iwaki, Scitech Div. Asahi Technl. Glass, Japan) in Dulbecco's modified 
Eagle's medium (DMEM) (Gibco, Grand Island, NY) supplemented with 
10% heat inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), 
lOOU/ml of penicillin and lOOmg/ml of streptomycin (Gibco, Grand Island, 
NY), in a humidified 5% CO2 atmosphere at 37 C. The media were changed 
every 3 days, and the cells were separated via trypsinizaion using 0.05% 




2.2.2.1. RNA extraction and Reverse Transcription -cDNA synthesis 
Total RNA was extracted from hepatocytes using RNeasy® Mini Kit 
(QIAGEN GmbH, Hilden, Germany). Briefly, cells were washed in PBS, 
collected and centrifuged at 2000 rpm for 5 minutes in 1.5 ml 
microcentrifuge tubes. The cells were then lysed by voitexing and pipetting 
in 350/il lysic buffer (with P-mercaptoethanol (P-ME) added). After that, 
350/xl of 70% ethanol were added and mixed with the lysate. The mixture 
was transferred to an RNeasy spin column. The column was centrifuged and 
washed in the specified washing buffer. Finally, the RNA was eluted with 
SOjLil of RNase free water. RNA was quantified by absorbance at 260nm. 
5jLig total RNA were reverse transcribed to cDNA with AMV reverse 
transcriptase (lOu/l/i) (Promega, Madison, WI) in a 20/xl reaction mixture 
containing lOX reverse transcription buffer (Promega, Madison, WI), 25mM 
MgCl2 (Promega, USA), lOmM dNTP mix (Promega, Madison, WI), 40U//li1 
rRNasin® RNase Inhibitor (Promega, Madison, WI) and SOO/xg/ml random 
primers (Promega, Madison, WI) for the reaction to be performed in the 
PGR system as the following condition: 
Steps Conditions Time 
1 3 7 � C lOmin 
2 4 2 � C 60 min 
3 99 °C 5 min 
The cDNA was then stored at -20 °C until further use. 
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2.2.2.2. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
We performed PGR to determine Bak mRNA expression after cDNA was 
made from the reverse transcription. Total RNA was used as a template for 
DNA synthesis. PGR was performed with each cDNA, ZBP-89, Bak and 
GAPDH primers, and Taq DNA polymerase (Roche diagnostics GmbH, 
Mannheim, Germany). We used GAPDH mRNA as an internal control. The 
primers used were detailed in Table 2.1. Reactions were carried out in a 
DNA Thermal cycler (Model GeneAmp PGR System 9700, Applied 
Biosystems, Singapore) for 35 cycles of amplification at an annealing 
temperature of 55 °C. The cycling parameters were set as follows: 
Steps PGR conditions Time 
1 95 °C 3mins 
2 95 °C 30sec 
3 5 5 � C 30sec 
4 72 30sec 
5 repeat step 2-4 for 35 cycles 
6 72 °C lOmins 
PGR products were then loaded on a 1.5% agarose gel in TBE buffer for 
electrophoresis and observed under ultraviolet light. The size of the PGR 
product was checked to confirm expression of respective fragments. 
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Table 2.1. Primers used for RT-PCR 
Expected size 
ZBP-89 Forward primer 5'-ATGAGGATGGATCACTTGG 
Reverse primer 5'-GCACATACGTTTATCTTTCAATAC 360bp" 
Bak Forward primer 5'-GACACAGAGGAGGTTTTCCGC 
Reverse primer 5 ‘ - AGC ATG A AGTCG ACC ACG A AG 400bp 
Bcl-2 Forward primer 5'-CATGTGTGGAGAGCGTCAA-3' 
Reverse primer 5'-CAGAGACAGCCAGGAGAAATCA-3' 184bp 
GAPDH Forward primer 5'-CACTGCCACCCAGAAGACTG 
Reverse primer 5'-TCCACCACCCTGTTGCTGTA 435bp 
2,2.3. Western blotting. 
2.2.3.1. Sample preparation 
For each cell line, total cell lysate was extracted for detection of endogenous 
ZBP-89 and Bak expression. Cells were collected by trypsinization and 
washed twice by PBS. They were then centrifuged at 2000 rpm for 5 
minutes. The PBS was aspirated and the cell pellet was resuspended in 500 
li\ of ice-cold RIPA lysis buffer (Ix PBS, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% SDS, with 10 /xl of protease inhibitors cocktail and 10 
ix\ of PMSF (10 jUg/ml). The tubes were then incubated on ice for 30 
minutes. After that, the cells were disrupted and homogenized by passing 
through a 21G needle. Another 10/xl of PMSF was added to the lysate and 
was incubated on ice for 30 minutes again. The samples were centrifuged at 
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lOOOOg for 10 minutes at 4°C and the supernatant was collected for protein 
assay. 
2.2.3.2. Measurement of protein concentration 
Protein concentration was determined by using Bio-Rad DC (detergent 
compatibility) Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA). 
Reagent A，was first prepared by adding 20 (xl of reagent S to 1 ml of 
reagent A. Five protein standards were prepared by serial dilution of 1.4 
mg/ml bovine serum albumin (BSA) standard to construct the standard 
curve: 125 jLig/ml, 250 /zg/ml, 500 jUg/ml, 1 mg/ml, 1.4 mg/ml. 5/xl of 
standards or samples were added to a microplate in duplicate and 25 
reagent A，was also added. After that, 200 ix\ of reagent B were added and 
mixed by gently shaking. The plate was incubated at room temperature for 
15 minutes and absorbance was read at 750 nm by a microplate reader. The 
concentration of the protein samples was calculated from the standard curve. 
2.2.3.3. Sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
(SDS-PAGE) 
An equal amount of proteins (SOjUg) was separated on a SDS/ 
polyacrylamide gel. Protein samples were first diluted in RIPA to the same 
concentration with 5x SDS loading dye (60mM 4x Tris-Cl/SDS, 25% 
glycerol, 2% SDS, P-ME, 0.1% bromophenol blue) added. SOjLig samples 
were first boiled at 100 °C for 5 minutes before loading into a 14% resolving 
polyacrylamide gel (3.5 ml of 40% acrylamide/Bis, 2.5 ml of 4X 
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Tris-Cl/SDS, pH 8.8’ 4 ml of H2O，10% APS, TEMED) with 5% stacking 
gel (0.625 ml of 40% acrylamide/Bis, 1.25 ml of 4X Tris-Cl/SDS, pH 6.8，3 
ml of H2O, 10% APS, TEMED) set above it. lO/xg of Full-Range Rainbow 
Molecular Weight marker (Amersham Biosciences, Buckinghamshire, UK) 
were also loaded to the gel as a protein size indicator. The protein was 
resolved with lOOV for 2 hours. After electrophoresis, the gel was 
transferred onto a nitrocellulose membrane (Hybond ECL, Amersham 
Biosciences Inc) in the ice cold transfer buffer (25 mM Tris, 192 mM 
glycine, 20% methanol, pH8.3). The transferring process was run at lOOV 
f o r i hour at 4 °C. 
2.2.3.4. Immunoblotting of protein 
The membrane was blocked in 5% non-fat milk for 1 hour followeci by 
washing with Tris-buffered saline (200 mM Tris-Cl, 137 mM NaCl, pH 7.5) 
plus 0.1% Tween 20 (TEST) for 3 times, 5 mins each, the membrane was 
then incubated with the primary antibody at 4 °C overnight. After incubation, 
the membrane was washed with TEST for 10 mins, and then 5 mins each for 
3 times before incubated with the secondary antibody for 1 hour. The 
membrane was washed again with TEST using the same procedure 
described above. It was then transferred to a flat surface and covered by 
1.5ml of enhanced chemiluminescence system solution (ECL), which was 
formed by mixing reagent A and B (Amersham Biosciences, 
Buckinghamshire, UK). After incubation for 1 minute, excess ECL solution 
was drained away and the membrane was wrapped in Saran-wrap. It was 
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then fixed in an x-ray film cassette with protein facing the Hyperfilm^^ 
(Amersham Biosciences Buckingham-shire, UK), and was exposed within 
10 minutes. The film was finally developed by the film processor. The 
membrane can be re-used by washing in PBS for several times and then 
stripped with stripping buffer (2% SDS, lOOmM P-mercaptoethanol, 
62.3mM Tris-HCL, pH6.8) for 30 mins at 55°C. After washing extensively 
with PBS, the membrane was reprobed with another antibody. Typically, a 
blot was used for two to three times. The primary antibodies used in this 
work are anti-ZBP-89 mouse polyclonal (Abnova corparation) (1:1000 
dilution), anti-Bak rabbit polyclonal (Cell Signalling Technology, Inc) 
(1:1000), Bcl-2 mouse IgGl (Santa Cruz Biotechnology, Inc) (1:1000), 
mouse anti-cytochrome c (ZYMED Laboratories) (1:1000) and anti-actin 
goat polyclonal (Santa Cruz Biotechnology, Inc). The corresponding 
horseradish peroxidase (HPR) conjugated secondary antibodies (rabbit 
anti-mouse, mouse anti-rabbit, goat anti-mouse IgGl and bovine anti-goat) 
were from Santa Cruz Biotechnology, Inc. and used in 1: 2000 dilution. 
2.2.4. Adenovirus ZBP-89 infection and assessment of cell proliferation. 
Replication-deficient recombinant Ad-ZBP-89 expressing 3.5kd full-length 
Flag-tagged human ZBP-89 cDNA, was kindly made in our lab previously 
by Miss Chun Suk-Ying using Ad Easy™ vector system (Agilent 
Technologies, CA). The viral titers were determined according to the 
Adeno-X Expression system (Clontech, Palo Alto,CA) user's manual. A 
wide range of multiplicity of infection (MOI) from 10 to 1000 was tested for 
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virus infection. The efficiency of virus infection was poor when MOI was 
below 20. The cytotoxicity became apparent when MOI was over 100. 
Therefore, we chose MOI 100 as a standard dose for virus infection. MTT 
(3_(4^5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was 
used to quantify cell proliferation based on cell viability (Chi et al; 2004, 
Zeng et at; 2007). Briefly, human liver cells were seeded in 96-well plates 
(Becton Dickson Labware, Franklin Lakes, NJ) in a density of 1000 cells/ 
100/xl/ well and incubated overnight to allow cells to attach to the plate. 
Cells were incubated with Ad-ZBP-89 at the multiplicity of infection (MOI) 
10，100，250, 500，800 for 0，10，24，48’ 72hrs in duplicate, two wells of 
each line were empty for blank control. Having added lO/il MTT solution 
(5mg/ml in PBS) (Sigma-Aldrich, St. Louis, MO) to each well, cells were 
incubated for another 4 hours at 37 °C in a humidified atmosphere, 5% CO2 
in order to allow MTT to be metabolized. The medium was aspirated and 
cells were solubilized in 200jLil of dimethylsulphoxide (DMSO) 
(Sigma-Aldrich, St. Louis, MO) to resuspend the formazan dye. The plates 
were shaken gently and incubated in dark for 30 minutes. Absorbance was 
measured by a microplate reader at 560nm with a reference wavelength of 
670nm. Cell viability was presented as % of the control cells (non-treated) 
conditions (the absorbance of the treated cells divided by the absorbance of 
the control cells and multiplied by 100). 
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2.2.5. Detection of apoptosis. 
2.2.5.1. Cell fixation 
The 4 tested liver cells at a density of 3x10^ cells/ 2ml/well were seeded in 6 
well plates (Becton Dickson Labware, Franklin Lakes, NJ) and incubated 
overnight to allow cells to attach to the plate. Cells were then treated by 
Ad-ZBP89 (MOI 100) and incubated for five different time points at 0, 10， 
24, 48, 72 hrs before the collection of the cells. Flow diagram of 
APO-DIRECT™ Apoptosis assay kit (Chemicon international, SanDiego, 
CA) was used for the detection of apoptosis cells. Cells were first 
trypsinized and collected in a 12x75min centrifuge tube. They were 
centrifuged at 200rpm for 5 mins and then washed in 1ml cold PBS. The 
supernatant was decanted and the cells were resuspended in 1% (W/V) 
paraformadehyde in PBS, pH7.4 at a concentration of 1x10^ cells/ml. The 
cell suspension was placed on ice for 30-60 mins. After centrifuging cells 
for 5 mins at 2000rpm, the supernatant was discarded and the cell was 
washed in 2ml PBS. The cell pellet was resuspended in ice-cold 75% (v/v) 
PBS diluted ethanol in a tube by gently vortexing. They were then to stand 
for a minimum of 12hrs at 4°C in order to permeabilize the plasma 
membrane prior to staining for apoptotic cells. 
2.2.5.2. Flow cytometry analysis 
Apoptosis was measured according to the protocol provided by the kit. After 
repeatedly washing, incubating and staining procedures, cell pellets were 
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finally resuspended in 0.5ml of lOOmg/L propidium iodide (PI) and 
lOmg/mL RNase A solution. After 30 mins of incubation in dark at room 
temperature, cells were analyzed by FACS flow cytometer and the result 
was presented as % fold of Oh control conditions. 
2.2.6. RNA interference (siRNA). 
2.2.6.1. ZBP-89 SiRNA 
The 4 tested cells (3x10^ cells/well) were each seeded in 6 well plates and 
incubated in 2ml of the normal growth medium containing serum without 
antibiotics overnight to allow cells to attach to the plate. The totals of 50|iM 
of annealed, purified and desalted double-stranded siRNA tagged against 
ZBP-89 and the negative control were purchased from Ambion Silencer 
Select Pre-designed siRNA (Ambion, Applied Biosystems). The 
pre-designed siRNA sequences targeted the exon 5 of the human ZNF148 
(NM_021964). The positive control siRNA targeted GAPDH and the 
negative control siRNA consisted of a scramble sequence that would not 
lead to the specific degradation of any known cellular mRNA. PBS was 
treating as the positive control. The pre-designed siRNA was first 
resuspended in the provided Nuclease-free water at a convenient 
concentration for diluation. It was then transfected into the cultured cells in 
80% confluence using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA, 
USA) and the transfection was carried out according to the manufacturer's 
recommendation. Briefly, for each well of cells to be transfected, 3|il 
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LipofectAMINE 2000 was diluted in 100^1 Opti-MEMI reduced serum 
medium (Gibco, Grand Island, NY), mixed gently and incubated at room 
temperature for 5 min. Subsequently, a mixture of siRNA (40 pmol ZBP-89 
siRNA or control siRNA diluted in 100 p.! Opti-MEM reduced serum 
medium) was added and incubated for 20 min. The optimum concentration 
of ZBP-89 siRNA was measure and adjusted to 40nM for the following 
experiments. Six hours after transfection, the medium was replaced with 
growth media containing serum and the cells were cultured at 37 C in a CO2 
incubator for another 18h. The cells were harvested for RT-PCR, cell 
viability assay and Western blot on Bcl-2 family proteins after the indicated 
time period. 
2.2.6.2. Bak siRNA 
For small interfering RNA-mediated down-regulation of Bak, it was a 
target-specific 20-25nt siRNA (sc-29789, Santa Cruz Biotechnology, Inc.) 
designed to knock down Bak gene expression in human cells. Control 
siRNA-A (sc-37007) is a non-targeting siRNA designed as a negative 
control. Cells were transiently transfected Bak siRNA (50nM) with 
LipofectAMINE 2000 according to the above protocol and analyzed its 
protein and RNA expression 24-72h after transfection. Furthermore, Bak 
siRNA transfected cells were treated with Ad-ZBP-89 (MOIlOO) for 24-72h 
in a separate experiment, cells were harvested and analyzed Bak expression 
by Western blot and flow cytometry for apoptosis detection. 
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2.2.7. Statistical analysis. 
All results are expressed as mean土SD and represent at least three independent 
experiments for each group. Differences between groups were examined for 
statistical significance using Student's t-test (paired, two sided) or one way 
ANOVA followed by Student's t-test. P< 0.05 was used to indicate a 
statistically significant difference. 
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2.3. Results 
2.3.1. Expression of ZBP-89 and Bak in human liver cell lines 
We first determined the endogenous levels of ZBP-89 and Bak present in 
Hep3B, PLC/PRF/5, SK-Hep-1 and Chang liver cancer cell lines. We 
assessed their mRNA and protein expression by RT-PCR and Western 
blotting. We found that both were expressed in all four tested cell lines 
(Fig.2.3), indicating expression of endogenous ZBP-89 and Bak in these cell 
lines. 
A. 
M 1 2 3 4 
^BP-eg 360bp 
Bak 400bp 
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Fig.2.1A.Expression of ZBP-89 and Bak mRNA in human liver cancer cell 
lines. Total RNA was isolated from human liver cell lines (Hep3B, 
PLC/PRF/5, SK-Hep-1, Chang), reverse transcribed using random primers, 
and amplified by PCR using specific primers for ZBP-89, Bak or GAPDH 
respectively. The RT-PCR products were electrophoresised on ethidium 
bromide-containing agarose gels. M: lOObp ladder marker, Lanel Hep3B, 
Lane2 PLC/PRF/5, Lane3 SK-Hep-1, Lane4 Chang. Expected sizes for 
ZBP-89, Bak and GAPDH were 360bp, 400bp and 435bp respectively. Fig. 
2. IB.Western blot analysis. Total proteins were obtained from human liver 
cell lines Hep3B, PLC/PRF/5, SK-Hep-1, Chang, resolved on 12% 
polyarcylamide gel electrophoresis, transferred to nitrocellulose and probed 
with an antibody against ZBP-89 and Bak. The blots were stripped and 
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reprobed with antibody to (3-actin which was used as a loading control. The 
figures were representative of three independent experiments showing 
similar trend. The molecular weights of proteins are indicated. Lanel Hep3B, 
Lane2 PLC/PRF/5, Lane3 SK-Hep-1, Lane4 Chang. 
2.3.2 Effects of Ad-ZBP-89 on proliferation of human liver cancer cells 
To investigate the effects of ZBP-89 on the proliferation of human liver 
cancer cells, we analyzed cell proliferation using cell viability assay. Cells 
were treated with Ad-ZBP-89 (MOI 0-800). Ad-ZBP-89 significantly 
reduced cell viability of Hep3B，PLC/PRF/5, SK-Hep-1 and Chang cells in a 
dose and time dependent manner as determined by MTT assay (Fig.2.2). 
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B. PLC/PRF/5 cell viability 
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D. Chang cell viability 
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Fig.2.2. Effects of Ad-ZBP-89 on cell viability of human liver cancer cells. 
Cells (Hep3B, PLC/PRF/5, SK-Hep-1 and Chang) were treated with 
Ad-ZBP89 MOI 0, 10’ 100，250, 500，800 for 10，24，48 and 72h. The data 
were represented as mean 土 SD for 3 independent experiments. It was 
assessed by MTT assay and showed the percentage of cell growth 
compared with the untreated cell lines. The cell proliferation was 
obviously inhibited by Ad-ZBP-89 in a dose- and time-dependent manner 
(p<0.05, Student's t-test). Based on this result, 24h treatment with MOI 
100 Ad-ZBP-89 was selected to be applied for the further experiments. 
Figures 2.2.A, B, C and D represent experiments using Hep3B, 
PLC/PRF/5, SK-Hep-1 and Chang cells, respectively. 
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2.3.3. ZBP-89 activates Bak gene expression 
We next used Western blot and semi-quantitative RT-PCR to determine the 
protein and mRNA level of 2 Bcl-2 family members, Bak and Bcl-2, in the 
control cells as well as cells infected with MOI 100 Ad-ZBP-89 for 10，24, 
48 and 72h. Both ZBP-89 and Bak levels were markedly increased in all of 
the cells and they achieved a maximal level after 24h of ZBP-89 infection, 
although Hep3B appeared to be effective 48h after the infection, indicating 
that Bak protein is induced by ZBP-89. Nevertheless, there was no 
significant difference of Bcl-2 expression between the ZBP-89 infected cells 
and the control cells for all tested cells. Fig.2.3.1 indicated the protein 
expressions of two Bcl-2 family members, Bak and Bcl-2, in HCC cells. 
Likewise, the expression of ZBP-89 and Bak mRNA (Fig.2.3.2) followed a 
similar pattern as the protein expression. 
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B. P5 cells protein expression 
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D. Chang cells protein expression 
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Fig.2.3.1 Western blots showing ZBP-89 and Bak expression in Hep3B, 
PLC/PRF/5 SK-Hep-1 and Chang cells. Whole cell lysates were extracted 
from non-infected cells as well as cells infected with MOIlOO concentration 
of Ad-ZBP-89 for 10，24，48，72h. They were separated by 12% SDS-PAGE 
and then the blot was probed with antibody to ZBP-89 and Bak, whereas 
anti-p-actin antibody was used as the control to detect equal loading of 
lysates in each lane. Experiments were repeated three times, and a 
photograph of a representative autoradiograph is shown. Figures 2.4.A, B, C 
and D represent experiments using Hep3B, PLC/PRF/5, SK-Hep-1 and 
Chang cells. 
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A. Hep3B mRNA expression 
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C. SK-Hep-2 mRNA expression 
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Fig.2.3.2 RT-PCR analysis of ZBP-89, Bak and Bcl-2 mRNA expression in 
Hep3B (A), PLC/PRF/5 (B), SK-Hep-1 (C) and Chang (D) cells. 8昭 of 
total RNA was reverse transcribed. The cDNA was amplified 
simultaneously over 30 cycles for ZBP-89, Bak and Bcl-2 using specific 
primers listed in Table 2.1. The expected PCR product of ZBP-89, Bak and 
Bcl-2 are 360bp, 400bp and 184bp respectively. GAPDH gene served as an 
internal control. 
2.3.4. Translocation of cytochrome c from mitochondria to cytosolic 
fraction 
It is well known that cytochrome c should confine in the mitochondria of 
unstimulated cells, and upon apoptotic stimulation, it translocates from the 
mitochondria to the cytosol. Accompanied the up-regulation of Bak was an 
increase of cytochrome c in the cytosol, PLC/PRF/5 and SK-Hep-1 cells 
showed an obvious translocation of cytochrome c from mitochondria to 
cytosol 24h after infection of ZBP-89 (Fig.2.4) which enhance Bak before 
the translocation effect. The expression of cytochrome c reduced in 
cytosolic fraction as Bak level decrease after 48 and 72h of ZBP-89 
infection (Fig.2.3). These results indicated that the increase of Bak and the 
release of cytochrome c into the cytosol were associated with the apoptosis 
induced by Ad-ZBP-89. 
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Fig.2.4. Ad-ZBP-89 induced the release of cytochrome c. we treated the four 
tested cells by MOIlOO Ad-ZBP-89 for Oh, 24h, 48h and 72h. The 
translocation of cytochrome c from mitochondria (Mito) to cytosol (CTS) 
was detected by Western blot. 50|xg of the protein fractions were used and 
collected separately. Equal loading was confirmed by measuring actin 
protein in the cytosol. Experiments were repeated three times and similar 
results were obtained. 
2.3.5. Apoptosis rate treated with ZBP-89 in human liver cancer cells 
To further examine whether apoptosis contributes to the ami-proliferate 
effect of ZBP-89 on the liver cells, we performed TUNEL assay to detect 
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apoptosis. It was found that Ad-ZBP-89 (MOI 100) treatment resulted in an 
increase in apoptotic rates in all cells tested. Compared with untreated cells, 
ZBP-89 effectively increased the apoptotic rates by over 25 folds in the 
infected SK-Hep-1 cells treated for 24hr (Fig.2.5). Similar results were 
obtained in the other ZBP-89 infected PLC/PRF/5 cells and Chang cells. 
Hep3B has a relatively low apoptosis rate. 
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Fig.2.5 Results of MOI 100 Ad-ZBP-89 on apoptosis in cells (Hep3B, 
PLC/PRF/5, SK-Hepl and Chang). Cells were treated with MOI 100 
Ad-ZBP-89 for 0，10, 24，48 and 72h. After the treatment, apoptosis was 
detected by TUNEL assay. The results are expressed as the relative rate of 
apoptotic cell fraction as compared to untreated controls in the mean of 土 
SD of 3 independent experiments. The statistically significant differences 
from untreated cells were labelled as * p<0.05 and * * pcO.Ol. 
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Some consistent results were observed in MTT and TUNEL analysis among 
the 4 treated cells. PLC/PRF/5, SK-Hep-1 and Chang cells infected with 
ZBP-89 were more sensitive to cell death when comparing with Hep3B cells. 
It is likely that this difference may due to different p53 status in the cells. 
The ZBP-89-inducing apoptosis effect may work more effectively on HCC 
cells with wild-type or mutant p53 gene, which proved by the non-tumor 
Chang liver cells, than on cells which lack of p53 gene, like Hep3B cells. 
2.3.6. The silencing effect of ZBP-89 siRNA 
2.3.6.1. ZBP-89 siRNA reduced Bak mRNA expression 
We determined the effects of siRNA-mediated ZBP-89 knockdown 
(silencing) on the regulation of Bak gene in the human liver cells. A 
pre-designed double stranded ZBP-89 siRNA and a specific non-targeting 
negative control siRNA were transfected into Hep3B, PLC/PRF/5, 
SK-Hep-1 and Chang at a concentration of 40nM. This concentration proved 
effectively to suppress the Bak expression after 48h and we will use the 
same concentration for ZBP-89 siRNA in our following experiments. Four 
tested cells were transfected with ZBP-89 siRNA or non-specific control 
siRNA at a concentration of 40nM. Cells treated with PBS were used as 
mock control. The expression of ZBP-89 and Bak mRNA were assayed 48h 
after treatment. Total RNA samples were subjected to RT-PCR using primer 
sets described in Table 2.1. The expected PGR product of ZBP-89 and Bak 
is 360bp and 400bp. The results indicated that ZBP-89 siRNA completely 
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blocked both ZBP-89 and Bak expressions in SK-Hep-1 cells and it greatly 
reduced Bak expression in PLC/PRF/5 and Chang cells. However, there is 
only a slight decrease of Bak mRNA in Hep3B cells. In general, the results 
showed that ZBP-89 siRNA reduced the basal level of Bak in HCC cells 
(Fig.2.6.1). 
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Fig.2.6.1. Effect of ZBP-89 siRNA on cell viability in the four tested cells. 
The mRNA expression of ZBP-89 and Bak 48h after transfection with 
ZBP-89 siRNA is analyzed by RT-PCR. Both ZBP-89 and Bak mRNA 
expressions were significantly down-regulated by ZBP-89 siRNA showing 
in Hep3B cells (A), PLC/PRF/5 (B), SK-Hep-1 (C) and Chang cells (D). 
GAPDH served as an internal control. 
2.3.6.2. ZBP-89 siRNA increase Bcl-2 protein expression 
To determine whether ZBP-89-induced apoptosis in the cells was associated 
with change of Bcl-2 family, Bcl-2 and Mcl-l were then analyzed after 
treatment with ZBP-89 siRNA. Interestingly, transfection of siRNA to 
suppress ZBP-89 increased the anti-apoptotic Bcl-2 protein, whilst in the 
absence of Bak in both PLC/PRF/5 and SK-Hep-1 cells. A comparatively 
slight decrease of ZBP-89 and Bak expressions were also observed in 
Hep3B cells after transfection of ZBP-89 siRNA. Unlike PLC/PRF/5 and 
SK-Hep-1 cells, Hep3B seemed to have no change in Bcl-2 expression. In 
contrast, there was no detectable expression for Mcl-l in all tested cells. 
This finding probably suggested that ZBP-89 is important for maintaining 
the Bcl-2 basal levels in HCC cells. 
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A. Bak and Bcl-2 protein expression in Hep3B cell 
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C. Bak and Bcl-2 protein expression in SK-Hep-1 cell. 
Ad-ZBP-89 
(MOI100) 24h 48h - -
ZBP89 SiRNA - - 24h 48h -
(40nM) 
ZBP-89 — 一 , , 37kD 
Bak — 26kD 
Bcl-2 一一 一 … 25kD 
^^  . ’ __— 一 
Aclin rnmm 43kD 
Fig.2.6.2. Induction of Bcl-2 expression by siRNA ZBP-89 in HCC cells. (A) 
Hep3B, (B) PLC/PRF/5 and (C) SK-Hep-1 cells were either treated with 
ZBP-89 or its siRNA for the indicated times. Western blot analysis of Bak 
and Bcl-2 proteins was detected. Whole cell lysates (40|Ag) were resolved by 
12% polyacrylamide gel electrophoresis and the blot was probed with the 
relative antibodies. (3-actin served as a control for protein loading. The 
figures were representative of three independent experiments showing 
similar trend. 
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2.3.6.3. ZBP-89 siRNA increased cell proliferation 
Subsequently, we determined the effects of ZBP-89 siRNA on the regulation 
of cell growth in the human liver cells. After transfection of ZBP-89 siRNA, 
the cell viability was assayed by MTT described in 'Materials and methods' 
2.2.4. SK-Hep-1 cells gained the highest growth rate; the results showed that 
ZBP-89 siRNA increased the cell viability by 14，18 and 23% in SK-Hep-1 
cells after 24h, 48h and 72 h treatment, respectively. Similar trend was also 
observed in PLC/PRF/5 and Chang cells. Fig.2.6.3 also showed that the cell 
growth in Hep3B was approximately 2.5-fold lower than SK-Hep-1 cells 
assayed in 48h. 
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D. Chang cell viability 
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Fig.2.6.3 Proliferative effect of ZBP-89 siRNA on human liver cancer cells. 
Cells were transiently transfected with 40nM concentrations of ZBP-89 
siRNA or negative control siRNA in different time points (24h, 48h and 
72h). Cell viability was assessed by MTT assay. Results are expressed as 
percentage of cell viability with reference to the untreated control at 
indicated times. The data represent the mean 土 SD of 3 independent 
experiments. * and ** represents the P value of p<0.05 and pcO.Ol 
respectively. Figures 2.6.3A, B, C and D represent experiments using 
Hep3B, PLC/PRF/5, SK-Hep-1 and Chang cells. 
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2.3.7. The silencing effect of Bak siRNA 
2.3.7.1. The combined effect of Bak siRNA and ZBP-89 reduce Bak 
protein expression in HCC cells 
To further determine whether the antiproliferation effect of ZBP-89 is 
responsible for the induction of Bak and contributes to induce apoptosis, 
Bak siRNA was first used in cells transfection to examine the expression of 
Bak, followed by flow cytometry for apoptosis assay. We first transfected 
with 50nM Bak siRNA or non-specific control siRNA as negative control, 
6h after treatment, cells were infected with MOI100 Ad-ZBP-89 for another 
24, 48 and 72h. The protein expressions of Bak were assayed by Western 
blot (Fig.2.7.1). Bak was completely blocked by its siRNA in PLC/PRF/5, 
SK-Hep-1 and Chang cells after 24h, whereas a weaker blocking effect on 
Bak was seen in Hep3B cells after 48h. Treatment with both Bak siRNA and 
Ad-ZBP-89 showed that Bak expression reappeared 72h after ZBP-89 was 
infected in Hep3B cells. Bak in PCL/PRF/5, SK-Hep-1 and Chang cells on 
the other hand still kept silenced by its siRNA after 72h of the infection 
period. These results suggested that ZBP-89 may have a direct regulating 
effect on Bak expression. 
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A. Bak protein expression in Hep-3B cell 
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C. Bak protein expression in SK-Hep-1 cells 
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Fig.2.7.1 Silencing of Bak expression with siRNA and the combined effect 
of Ad-ZBP-89 in HCC cells. The cells were cultured in 6-well plate and 
transfected with 50nM of Bak interfering or control RNA for 6h. After 
transfection, cells were infected with Ad-ZBP-89 (MOI 100) for 24h, 48h 
and 72h and whole cell lysates were prepared for analyzing Bak expression 
by Western blot. Equal loading was confirmed by probing with antibodies 
against actin. Results showed that Bak level was silenced after treatment 
with siRNA in all tested cells. Fig.2.7.1 showed the Bak expression in A: 
Hep3B cell, B: PLC/PRF/5 cell, C: SK-Hep-1 cell and D: Chang cell. 
2.3.7.2. The combined effect of Bak siRNA and ZBP-89 reduce the rate 
of apoptosis in HCC cells 
To test whether ZBP-89-induced apoptosis reduced by Bak siRNA, TUNEL 
assay was performed to detect the apoptosis rate on these co-transfected 
cells. ZBP-89 treatment after Bak siRNA resulted in a decrease of apoptotic 
rates in both PLC/PRF/5, SK-Hep-1 and Chang cells. On the other hand, an 
average of 20 fold increases is measured in Hep3B cells 72h after ZBP-89 
infection, in addition with the Bak siRNA blocking effect. Hep3B were 
determined to have the highest apoptosis rate among the tested HCC cells in 
this combined treatment, this may due to a comparatively low blocking 
effect of Bak siRNA on Hep3B cells. Fig 2.7.1 showed the reduction of 
apoptosis is due to low expression of pro-apoptotic Bak level, which showed 
previously in Fig.2.7.2, in all tested HCC cells. 
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Fig.2.7.2 Cells were first transfected with siRNA specific for Bak (50nM) or 
control siRNA. 6h after transfection, cells were subjected to MOIlOO 
Ad-ZBP-89 for 24h, 48h and 72h. Cells were then harvested and analyzed 
by flow cytometry for apoptosis. Assays were performed in triplicates and 
are representative for at least three independent experiments. Values are 
means 土 SD with *p<0.05. 
2.4. Discussion 
Hepatocellular carcinoma is the prevalent tumour in human and the 
prognosis of HCC is still poor. Despite of remarkable advances in diagnostic 
techniques and screening treatment during the past 25 years, the survival of 
HCC does not appear to have significantly improved. In recent year, ZBP-89 
transcription protein has been demonstrated to induce cell cycle arrest and 
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apoptosis in various cancer cell lines (Bai et at; 2004). ZBP-89 is thinking to 
be a potent inducer of apoptosis in liver cancer cells. In this study, we found 
that induction of ZBP-89 transcription factor expression in liver cancer cells 
can lead to cell growth arrest and apoptosis. To clarify whether the 
mechanism of ZBP-89 expression determines the apoptotic response of 
HCC cells, we assessed the effect of various levels of expression of ZBP-89 
on different p53 status HCC cell lines, discovering a ZBP-89 regulated Bak 
(pro-apoptotic Bcl-2 family protein) expression system. 
In the current study, we are the first to discover the regulation of ZBP-89, 
established in the adenoviral mediated gene, on the Bak expression system 
to explore the role of ZBP-89 in cell death and apoptosis in liver cancer cells. 
ZBP-89 is a Kruppel-type transcription factor that requires zinc for its 
function and is ubiquitously expressed (Merchant JL, Iyer GR et al; 1996). 
Using RT-PCR and Western blot analyses, we determined the levels of 
endogenous ZBP-89 and Bak in Hep3B, PLC/PRF/5, SK-Hep-1 and the 
normal Chang liver cells. Both RT-PCR (Fig.2.1A) and Western blot 
(Fig.2.1B) showed that the four cell lines had similar levels of endogenous 
ZBP-89, but, compared with PLC/PRF/5, SK-Hep-1 and the normal Chang 
liver cells, the endogenous levels of Bak were lower in Hep3B cells. When 
the cells were infected with adenovirus mediated ZBP-89, Bak protein and 
mRNA expressions, which shown in Western blot (Fig.2.4.1) and RT-PCR 
(Fig.2.4.2) analysis, were up-regulated in all tested cells. These results 
indicate that both ZBP-89 and Bak were expressed endogenously in the cells 
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and the Bak gene can be activated by exogenous ZBP-89. Our data also 
demonstrated that the death of the liver cancer cells; were due to apoptosis 
induced by high level of Bak expression mediated by ZBP-89 (Fig.2.3 and 
2.5). In addition, we also examined the expression of Bcl-2 after Ad-ZBP-89 
infection in all tested cells, as the response of anti-apoptotic Bcl-2 protein 
such as Bcl-2 and Mcl-l may affect the outcome of Ad-ZBP-89-mediated 
apoptotic effect. There was however no modulation of Bcl-2 mRNA and 
protein expression level (Fig.2.3) and no detectable of Mcl-l expression was 
observed on Ad-ZBP-89 treatment. All tested cells reached its maximum 
Bak expression 24hour after MOI 100 Ad-ZBP-89 was infected. Cells 
cannot grow healthily or even die in high virus concentration environment 
or long infection period. This is why Bak protein expression is not 
dependent on the dose or time of adenovirus ZBP-89 treated on cells. The 
translocation of cytochrome c from mitochondrial into the cytosol is also 
noticed in our experiment (Fig.2.4), indicating a clear marker of 
mitochondrial alterations in apoptosis. To further confirm ZBP-89 
specifically regulates Bak expression, small interfering RNA (siRNA) was 
used to silence endogenous ZBP-89 expression prior to examining the 
expression of Bak. Wild-type siRNA targeting ZBP-89 dramatically reduced 
ZBP-89 mRNA levels compared to the controls (Fig.2.6.1). Consistenfwith 
the ability of ZBP-89 to activate Bak expression, reduced levels of ZBP-89 
resulted in lose of Bak protein level (Fig.2.6.2). In addition, reduced ZBP-89 
levels increased Bcl-2 expression (Fig.2.6.2), suggesting that ZBP-89 is 
required to maintain the basal levels of this anti-apoptotic protein. There was 
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not a definite pattern to explain the relationship between the different p53 
states because the cell death induced by Ad-ZBP-89 could be seen in all 
cells tested. However, it appears that Hep3B with partially deleted p53 is 
least affected by ZBP-89. We herein showed that Bak is important for 
ZBP-89-induced apoptosis of HCC cells. Two lines of evidence support this 
conclusion: (i) ZBP-89 siRNA obviously reduced Bak expression in amid 
increase the cell proliferation (Fig.2.6). (ii) Silencing of the Bak gene by 
siRNA blocked ZBP-89-induced apoptosis in HCC cells(Fig.2.7.2), the Bak 
expression is also blocked by its siRNA after long period of Ad-ZBP-89 
infection (Fig.2.7.1). Our findings generally suggested that Bak might be an 
important mediator of ZBP-89-dependent apoptosis in HCC cells and, at the 
same time, ZBP-89 is proved to induced apoptosis in a p53 independent 
way. 
p53 independent pathways causing apoptosis are less well defined. They 
generally include pro-inflammatory signals and withdrawal of growth 
factors that in turn suppress survival factors such as Bcl-2 subsequently 
destabilizing mitochondrial membranes. Since most tumors contain at least 
one mutated p53 allele, effective treatment of these tumors by enhancing 
apoptosis will likely utilize pathways that exclude p53. An alternative 
mechanism considered was repression of Bcl-2 family members Mcl-l and 
Bcl-xl involved in survival, since these genes were strongly repressed by 
ectopic ZBP-89. Although repression of the anti-apoptotic protein is not 
shown in my study here, an increase of Bak protein expression and 
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translocation of cytochrome c to cytoplasm were our prominent findings. 
The extra-nuclear activities of p53 have been reported to involve its physical 
and functional interactions with certain members of Bcl-2 protein family, 
including Bax, Bak, Mcl-l, Bcl-xL and Bad (Mihara et al; 2003, Chipuk et 
al; 2004, Leu et al; 2004, Jiang et al; 2006). In those previous work 
employing affinity chromatography and mass spectrometry protocols, they 
identified Bak as p53 interacting partner at mitochondria (Leu et al; 2004), a 
finding subsequently confirmed by others (Lomonosova et al; 2005, Moll et 
at; 2006, Pietsch et at; 2007; Sot et al; 2007). 
Bak is an integral outer mitochondrial membrane protein and a key cell 
death initiator (Griffiths et al; 1999, Wei et al; 2000，Sundararajan et al; 
2001，Cuconati et al; 2003, Nijhawan et al; 2003, Gelinas & White; 2005， 
Adams & Cory; 2007). Commitment to apoptosis involves an activating 
conformational change in Bak, leading to formation of higher order Bak 
multimers, mitochondrial membrane permeabilization and the release of 
pro-apoptotic factors such as cytochrome c into the cytoplasm. Our study 
showed that ZBP-89 induced a p53 independent apoptosis by up-regulating 
the Bak expression in all HCC and normal cells tested. The anti-tumor 
mechanism of ZBP-89 responsible for induced cell death needs continuing 
carry on in the gene mediated level. 
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Chapter Three 
Identification of ZBP-89 protein as an apoptosis inducer to 
activate the pro-apoptotic Bak gene promoter 
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3.1. Introduction 
Liver is generally refractory to apoptosis induced by the p53 tumor 
suppressor protein, but the molecular basis remains poorly understood. A 
recent study showed that p53 transcriptional activation leads to enhanced 
expression of hepatic IGRBPl (insulin-like growth factor-binding 
protein-1). Exhibiting a previously unanticipated role, a portion of 
intracellular IGFBPl protein localizes to mitochondria where it binds to 
the proapoptotic protein Bak and hinders Bak activation and apoptosis 
induction (J. I-Ju Leu, and Donna L. George; 2007). Meanwhile, Rousseau 
B and collegues using a proteomic analysis on HCC and identified the 
overexpression in 4 tumors of RuvB-like 2 (RUVBL2), an ATPase and 
putative DNA helicase known to interact with beta-catenin and cellular 
v-myc myelocytomatosis viral oncogene homolog (c-myc). They showed 
that silencing RUVBL2 in HuH7 HCC cells reduced cell growth (P < 
0.001) and increased apoptosis, as shown by DNA fragmentation (P < 
0.001) and caspase 3 activity (P < 0.005). This was associated with an 
increased expression of several proapoptotic genes and with an increased 
conformational activation of Bak-1 and Bax (Rousseau B et al; 2007). 
Bcl-2 family proteins play a critical role in the regulation of apoptosis in 
HCC, treatment of a human HCC cell line, QGY-7703, with Taxol, an 
anti-cancer drug, induced apoptosis and Bcl-2 protein phosphorylation. 
Microscopic observation indicated that apoptotic bodies (0-15%) of 
Taxol-treated QGY cells appeared after 12 h of treatment, and gradually 
increased to 40% after 24 h and 70% after 48 h. Bcl-2 protein was 
phosphorylated in Taxol-treated QGY cells within 3 h of treatment, and 
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continued gradually up to 24 h. Other Bcl-2 family proteins, including Bax 
(a heterodimerization partner of Bcl-2), Bak were expressed, but at 
constant levels. 
Interestingly, in many HCC cells and tissues p53 or variety of chemicals 
have a direct apoptotic function at mitochondria that includes Bak binding 
and activation. This pro-apoptotic effect is also the only responding Bcl-2 
family protein in our study on different types of p53 HCC cells; therefore, 
we are going to focus on its expression and mechanism in addition with the 
zinc finger transcription protein. 
The Bak expression has been reported in normal gastrointestinal epithelium 
(Kiefer MC, Brauer MJ et al; 1995). In gastrointestinal epithelial tissues, the 
up-regulation of Bak expression during differentiation may help to ensure 
that cell turnover occurs in a normal fashion. However, it has been reported 
that gastric tumors have reduced Bak levels when compared with the normal 
muscosa (Krajewska M et al; 1996). Moreover, mutations of the Bak gene 
have been identified in human gastrointestinal cancers, suggesting that a 
perturbation of Bak-mediated apoptosis may contribute to the pathogenesis 
of gastric cancer (Kondo S, Shinomura Y et al; 2000，Sakamoto I, Yamada T 
et al; 2004). Several recent reports have demonstrated the feasibility of 
using gene transfers to treat gastric cancers (Tsunemitsu Y et al; 2004, 
Zhang C，Liu ZK et al; 2003). Transformed hepatocytes survive various 
apoptotic insults during their growth in vivo. However, molecular 
mechanisms that inhibit apoptosis and support their survival are not well 
understood. We here investigated the expression and the role of Bak in 
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human HCC by utilizing Bak gene transfer via plasmid vector. We 
determined the apoptosis inducing effects of Bak overexpression on HCC 
cells in vitro and the combined treatment in addition with the infection of 
ZBP-89, in order to explore a novel strategy for gene therapy liver cancer. 
The objective of this part of study was to identify the zinc finger binding 
protein (ZBP-89) as a transcription factor that regulates the expression of 
Bak promoter gene, a major pro-apoptotic Bcl-2 family protein in cancerous 
cells. The luciferase promoter assay revealed that the Bak promoter region 
-507 to -357 contained binding site for zinc finger transcription nuclear 
protein. Using the electrophoretic mobility shift assay (EMSA), binding of 
ZBP-89 protein to the Bak promoter region -457 to -407 was further 
identified. In co-transfection analysis, overexpression of Bak enhanced the 
activity of ZBP-89-incluced apoptosis and this enhancement was dependent 
on the putative ZBP-89 binding site in the promoter. 
Bak was mostly expressed in the 20 pairs surgically resected human HCC 
tissues when examined by Western blot analysis, and levels of its expression 
showed lower in nearly all HCC tissues compare with those of normal liver 
tissues. We conclude that lack of Bak expression in human HCC cells may 
inhibit normal apoptosis function in cells. Therefore, resistance to apoptosis 
may provide a disadvantage for normal cell growth and progression of 
developing cancer cells. 
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3.2. Materials and methods 
3.2.1. Cell lines and tissues. 
The human liver cancer cells Hep3B, PLC/PRF/5 and SK-Hep-1 and the 
normal Chang liver cells were grown in 100mm tissue culture disk in . 
DMEM supplemented with 10% heat inactivated fetal bovine serum, 100 
U/ml of penicillin, and 100 mg/ml of streptomycin, in a humidified 5% C02 
atmosphere at 37°C. The media were changed every 3 days, and the cells 
were separated using 0.05% trysin/0.53mM EDTA when they reached 
subconfluence. Twenty pairs of HCCs and adjacent nontumor counterparts 
were obtained at the time of surgical resection. Two samples were extracted 
after receiving HCC chemotherapy, and the other one sample is from the 
recurrence of HCC tissue. 
3.2.2. Transient Transfection and Luciferase activity assay. 
Cells were seeded in 12 well plates at a density of 1x10^ cells/well and 
allowed to reach 60-70% confluence. The cells were transiently transfected 
with Lipofectamine 2000 at a Lipofectamine/ DNA ratio of 3:1 in the 
absence of serum with 1.5 ^ig/well of the Bak promoter plasmid (10 
different Bak promoter fragments-Luc plasmids), pGL3-basic plasmid or 
pGL3-control plasmid. After 6h of transfection, cells transfected with Bak 
promoter-Luc were washed and treated with MOI 100 Ad-ZBP-89 in the 
presence of serum for a further 24h. Firefly and Renilla luciferase assays 
were then performed on cell lysates using the Dual-Lucifearse Reporter 
Assay System (Promega) as the manufactures's instructions. Control Renilla 
luciferase activity was used to determine transfection efficiency as well as to 
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caluculate the relative firefly luciferase activity (normalization) as a 
percentage of the Renilla lucifearse activity. The activation ratio (fold 
activation) was determined by dividing the normalized firefly luciferase 
courts in the presence and absence of ZBP-89. Results were obtained from 4 
independent experiments, and values are expressed as means 土 S D (p<0.05). 
Fig.3.1A showed an overview of the Bak promoter luciferase fragments 
which kindly given by Mr. Liu Han Ching, B, pGL3-basic vector map and C, 
pGL3-control plasmid map (adapted from www.promega.comy All Bak 
constructs were sequenced through the vector-insert junctions to ensure 












Fig.3.1A Schematic representations of the luciferase reporter constructs 
containing various lengths of the Bak promoter sequence are shown to the 
left. A series of DNA fragments with 5'deletions of the Bak promoter were 
amplified by PGR using the full length Bak plasmid (provided in our lab) as 
a template with the same reverse primer and various forward primers. The 
fragments were cloned into pGL3-Basic at Mlul and Xhol sites. The 
indicated constructs were transfected into 4 tested cells, Hep3B, PLC/PRF/5, 
SK-Hep-1 and Chang cells respectively. 
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Fig.3.1B. pGL3-Basic vector map. Various Bak promoter fragments resides 
between the Mlul (15) and Xhol (32) restriction sites. 
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Fig.3.1C. pGL3-Control plasmid map. This plasmid is used in monitoring 
transfection efficiency. 
3.2.3. Vector construction. 
3.2.3.1. Generation of expression constructs 
Five pairs of lOObp Bak cDNA were amplified by PCR using the complete 
DNA sequence of Bak gene (Human Bak-2 gene). Mlul restriction site was 
located at all forward primers and Xhol was located at the reverse primers. 
The sequences of primers for amplifying different fragments of Bak gene 
were shown in Table. 3.3 
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Table 3.3. Primers designed for pGL3-Bak plasmid 










PGR was performed using the Expand High Fidelit/Lus pcR System 
(Roche Diagnostic GmbH, Mannheim, Germany) in a volume of 40 by 35 
cycles of Imin at 95°, 30 sec at 55° and 1 min at 72° using Taq DNA 
Polymerase and a novel protein that mediated proofreading activity (Roche, 
Diagnostic GmbH, Mannheim, Germany). 
3.2.3.2. Agarose gel extraction 
Electrophoresis of the PCR products was done on a 1% agarose gel 
containing ethidium bromide in IX TBE buffer. QIAquick® Gel Extraction 
Kit (QIAGEN GmbH, Hilden, Germany) was used to purify the PCR 
product. The DNA fragments were excised from the agarose gel with a clean 
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blade and the slices were weighed in a 1.5 ml eppendorf. Three volumes of 
Buffer QG was then added to 1 volume of gel and was incubated at 50°C for 
10 minutes with constant vortex every 2-3 minutes during the incubation. 
One gel volume of 100% isopropanol was added to the samples after the gel 
was completely dissolved and mixed. The samples were then applied to the 
the QIAquick columns in 2 ml collection tubes and were centrifuged for 1 
minute. The flow-through was discarded and 0.5 ml of Buffer QG to the 
same columns and was centrifuged for 1 minute. 0.75 ml of Buffer PE with 
ethanol added before used was added to the columns and centrifuged for one 
minute. The flow-through was discarded and the columns were centrifuged 
for an additional 1 minute to remove residual ethanol. The columns were 
placed into a clean 1.5 ml microcentrifuge tubes, and finally the DNA was 
eluted with 30 i^l of H2O to the center of the QIAquick membrane and the 
columns were centrifuged at full speed for 1 minutie. 
3.2.3.3. Restriction enzyme digestion 
The purified PCR products and the pGL3-Basic luciferase vector (Figure 
3.IB) (Promega, Madison, WI) were digested with restriction enzymes Mlul 
(Promega, Madison, WI) and Xhol (Promega, Madison, WI). The reaction 
was carried out in a total volume of 30 jil in the following condition: 20 jjl 
of PCR product or 1 of vector, 3 \i\ of 10-fold diluted BSA (Promega, 
Madison, WI), 3 of lOX buffer D (Promega, Madison, WI), 0.5 i^l of 
Mlul, 0.5 of Xhol and desired volume of d d H � � . The reaction mixture 
was incubated in 37 °C for 3 hours. The digested products were then purified 
by agarose gel extraction as described in 2.1.2. 
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3.2.3.4. Ligation of vectors and gene of interest 
The digested PGR products and the linearized pGL3-basic luciferase vector 
was ligated in a volume ratio of 10 : 3 (insert : vector). A reaction in total 
volume of 15 \i\ was done in the following condition: 10 of PGR product, 
3 of pGL3, 1.5 Hi of lOX ligation buffer and 0.5 \i\ of T4 DNA ligase 
(New England BioLabs Inc., Ipswich, MA). The mixture was incubated at 
16°C overnight. Five Bak plasmids were obtained: pGL3-basic, pGL3_-706 
(-706 to -608), pGL3_-617 (-616 to -518)，pGL3—-527 (-527 to -428), 
pGL3_-437 (-437 to -338), pGL3_-347 (-347 to -287). 
3.2.3.5. Preparation of competent cells for transformation 
E.coli strain JM109 (Genotype: end Al, rec Al, gyrA96, thi, hsdRll (rk", 
mk+)，relAl, supE44, A( lac-proAB), [F' rraD36, proAB, laqt^ZAMiS]) 
(Promega, Madison, MI) was used for transformation of the plasmids. The 
cells were grown in 100ml LB (Luria Bertani) medium (lOg Tryptone, lOg 
NaCl, 5g yeast extract per liter) at 37°C shaker until the stage when O.D. 
reached 0.6 at 600nm. Then, they were separated into 2 tubes and kept at 
4°C for 15 minutes. Cell pellet was obtained by centrifuging the cultures at 
3000 rpm for 5 minutes. After removing the supernatant, 10ml ice cold 
CaCl2 (50mM, pH7) were added to each tube and the cells were left in ice 
for 15 minutes. Before pelleting, the tubes were poured together and the 
mixture was centrifuging at SOOOrpm for 5 minutes. The pellet was 
resuspended in CaCb (50mM, pH7) with 15% glycerol. The mixture was 
aliquoted into pre-chilled micro-centrifuge tubes and stored at -80°C. 
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3.2.3.6. Transformation of plasmid in competent cell 
E.coli strain JM109 was used for the cloning of plasmids. These clones were 
transformed into the E.coli.strain. Plasmids were introduced into JM109 by 
CaCl2 mediated transformation. The plasmids were incubated with the 
competent cells on ice for 10 minutes. It was then followed by heat shock 
for 45 seconds and the DNA-competent cells mixture was put back to ice 
immediately for 2 minutes. ImL LB medium was added to the cells and 
incubated at 37°C for 1 hour. The cells were then centrifuged at 6000 rpm 
for 1 minute and were resuspended in 100 of LB medium with lOOug/ml 
ampicillin. They were spread onto ampicillin containing agar (LBA) plates 
and incubated at 37°C overnight until single colonies could be isolated. 
3.2.3.7. Plasmid extraction by mini-prep 
The plasmids were extracted by following the protocol from QIAprep® 
Miniprep (QIAGEN GmbH, Hilden, Germany). A single colony was picked 
from each freshly streaked LBA plate and was inoculated in a culture of 5 
ml of LB medium containing lOOug/ml ampicillin. The cultures were then 
incubated at 37°C overnight with vigorous shaking at 250rpm. After the 
shaking, the bacterial cells were harvested by centrifuging at 6000rpm in a 
conventional, table-top microcentrifuge for 3 minutes at room temperature. 
The pelleted bacterial cells were then resuspended in 250 jLtl of Buffer PI 
with RNase A solution added. The suspensions were transferred to a 1.5 ml 
microcentrifuge tube and 250 of Buffer P2 was added to them. They were 
mixed thoroughly by inverting the tubes 4-6 times. Then, 350 /il of Buffer 
N3 was added to the lysates and was mixed immediately by inverting the 
tube 4-6 times. After that, they were centrifuged for 10 minutes at 
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13,000rpm. The supematants were applied to the QIAprep spin columns by 
pipetting and the columns were centrifuged for 1 minute. The flow-through 
was discarded. Each of the QIAprep spin column was washed by adding 0.5 
ml of Buffer PB and was centrifuged for 1 minute. Then, the column was 
washed by adding 0.75 ml of Buffer PE (with absolute ethanol added before 
used), and was centrifuged for 1 minute. The residual wash buffer was 
completely removed by centrifuging for an additional 1 minute. The 
QIAprep column was placed in a clean 1.5 ml microcentrifuge tube and the 
plasmid DNA was eluted with 30 jul of elution buffer (10 mM Tris.Cl, pH 
8.5) added to the center of each QIAprep spin column. The column was 
allowed to stand for 1 minute and then centrifuged for 1 minute to collect 
the DNA. 
3.2.3.8. DNA sequencing of the inserted gene 
The sequences of different Bak fragments were checked by ABI PRISM™ 
BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (Applied 
Biosystems, Foster City, CA). In each reaction, the following reagents were 
added: 200-500 ng of plasmid DNA as template, 8 jul of terminator ready 
reaction mix, 1.6 pmol of RV forward primer 3, 1.6 pmol of GL reverse 
primer 2，and desirable amount of ddHzO to a total volume of 20 jul. The 
mixture was placed in a thermal cycler GeneAmp PGR System 9700 for 30 
cycles: 9 6 � C for 30 seconds, 55 °C for 5 seconds and 60 °C for 4 minutes. 
The reaction was terminated at 4 °C until purifying. 
The purification steps were carried out by using spin columns. The gel 
material in the columns was tapped to the bottom and 0.8 ml of ddEbO was 
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0.5mM DTT, 0.5mM PMSF, 0.5mM NajVOs, pH7.9 and Ix Protease 
Inhibitor Cocktail, was added to the pellet obtained after 750g centrifugation. 
The pellet and the buffer B were mixed by gently pipetting and kept in ice 
for 15 mins. 30|il 10% Nondet NP-40 were then added, vortexed for 10s, 
and centrifuged at 10,000g for 30s for 4°C. The supernatant was discarded 
and the pellet was re-suspend in 50|il ice-cold extract buffer C，which 
consisted of 5mM HEPES, 26% glycerol, 1.5mM MgCb, 0.2 mM EDTA, 
0.5mM DTT, 0.5mM PMSF, 0.5mM NasVOs, pH7.9 and Ix Protease 
Inhibitor Cocktail. The pellet was homogenized with 10 strokes of Teflon 
homogenizer and then centrifuged at 10’000g for 20mins at 4°C to collect 
the supernatant (the nuclear fraction). The protein concentration was 
measured and the protein was stored at -70°C. 
3.2.5. Electrophoretic mobility shift assay. 
A standard electrophoretic mobility shift assay (EMSA) was used to further 
examine whether ZBP-89 protein from the human liver nuclear extracts can 
bind to the Bak promoter region -457/-407 (described in result). Cells were 
plated on a 6-well plate and upon confluence, transfected with pGL3-Bak 
promoter for 6hrs; cells were then treated with MOIlOO Ad-ZBP-89 for 
another 24h. At the end of the incubation, nuclear extract was prepared 
using the nuclear extraction reagent which described above and stored at 
-70�C until the assay was performed. Table 3.5 showed 3 pairs of Bak 
Gel-shift complementary oligonucleotides (50bp each) were annealed and 
biotinlated using biotin 3’ end-labeling kit (Pierce Chemical Co.), and the 
EMSA was carried out with the LightShift chemiluminescent EMSA kit 
(Pierce chemical Co.) according to the manufacturer's instruction. Briefly, 
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the binding reactions were analyzed by electrophoresis through a native 6% 
polyacrylamide gel in TBE. After transferring of the binding reactions to the 
nylon membrane, it cross-linked in a transilluminator and passed several 
chemiluminescence steps before expose to x-ray film to visualize the 
DNA-protein complexes. 
Table 3.5 Sequences of the oligonucleotides (antisence) for Biotin 
labelling in EMSA 
(1) 50bp from -507 to -458: 
5'-AATACATGAAATATACTTAATAAAAATTCAAATGTTATAGAACTGAAAAA-3' 
(2) 50bp from -457 to -408: 
5'-GATGAAAAGTAAAAACAACCTATTCCCCAGAGGTAGCCACTGTCCATAGT-3' 
(3) 50bp from -407 to -357 
5’-TTCTATTTTAGATTCTTTCCnTATACAAGATTATTATAGCTTCTATTTT-3， 
3.2.6. Overexpression of Bak. 
3.2.6.1 Bak vector construction 
Plasmid pcDNA3.1-Bak was kindly provided by Mr. Rocky Ho in our lab, 
which contained the Bak cDNA (636bp) between the restriction sites for 
NotI and Apal in the linear eukaryotic vector fragments (5.4Kb). The Bak 
sequence is based on the map from NM_001188. The ligation reaction was 
conducted with T4 Ligase. 
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The forward primer: 
5，-GCGGCCGCAAAATGGCTTCGGGGCAAGGCC 
The reverse primer: 
5，-GGGCCC GGAGTCATGATTTGAAGAATCTT 
181 cctccactga gacctgaaaa atggcttcgg ggcaaggccc aggtcctccc aggcaggagt 
241 gcggagagcc tgccctgccc tctgcttctg aggagcaggt agcccaggac acagaggagg 
301 ttttccgcag ctacgttttt taccgccatc agcaggaaca ggaggctgaa ggggtggctg 
361 cccctgccga cccagagatg gtcaccttac ctctgcaacc tagcagcacc atggggcagg 
421 tgggacggca gctcgccatc atcggggacg acatcaaccg acgctatgac tcagagttcc 
481 agaccatgtt gcagcacctg cagcccacgg cagagaatgc ctatgagtac ttcaccaaga 
541 ttgccaccag cctgtttgag agtggcatca attggggccg tgtggtggct cttctgggct 
601 tcggctaccg tctggcccta cacgtctacc agcatggcct gactggcttc ctaggccagg 
661 tgacccgctt cgtggtcgac ttcatgctgc atcactgcat tgcccggtgg attgcacaga 
721 ggggtggctg ggtggcagcc ctgaacttgg gcaatggtcc catcctgaac gtgctggtgg 
781 ttctgggtgt ggttctgttg ggccagtttg tggtacgaag attcttcaaa tcatgactcc 
Figures.2A. Primer sites amplifying the full length Bak gene. The blue 
arrow' represents the forward primer and the pink arrow represents the 
reverse primer. 
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Figure 3.2B Vector map of pcDNA3.1 (+) 
cnhatcci region n. end) 
689 CATTGACGTC AATGGGAGTT TGTTTTGGCA CCAAAATCAA CGGGACTTTC CAAAATGTCG 
749 TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT 
3'end ofM NfV > 
1 putative Uanscriplbna] start ^ 
809 AAGCAGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAC TGGCTTATCG AAATTAATAC 
T7 p«>m<xcr.}yin«r biiKting site \'he f Pmt I AflU H»td in Axpl 181 Kpn I 
869 GACTCACTAT AGGGAGACCC AAGCVGGCTA GcisTT—AAAi TTAA(k;TTG'G TACCGAGCTC 
BamHl S wX I* fi. j>R 1 Ea>K V iS.«Xl* | No! I | Xho\ 
929 dcATCCACTA GTCCAGTGTG GTGGAATTCT GCXGATATCC AcicACA^TGG C6GCCGCTCG 
I Dra n I钟 I I Pme I 广DNiU.I/BGH f<rvcise piimingiitc 
989 AGTCTAGA'GG G6CCGYTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC 
1049 CATCTGTTGT TTGCCCCTCC CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG 
BGH(>ftly(A) site 
1109 TCCTTTCCVA ATAAATGAQ GAAATTGCAT 
Figure 3.2C Multiple cloning sites of pcDNA3.1 (+). The restriction 
enzyme sites used are shown in red boxes. 
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3.2.6.2. Gene transfer and cellular apoptosis detection. 
Hep3B, PLC/PRF/5, SK-Hep-1 and Chang cells were transiently transfected 
with pcDNA—Bak plasmid using the protocol similar to siRNAs or pGL3 
luciferase Bak fragments transfection. 3x10^ cells were seeded into each 
well of 6-well culture plate with complete medium for a day before 
transfection. 2 fig of plasmid DNA and 5 |il of Lipofectamine 2000 were 
each diluted in 100 pi of serum free Opti-MEMI medium. They then mixed 
together and incubated at room temperature for 20 mins. The diluted 
DNA-Lipofectamine complexes were added to each well with extra 800 [i\ 
of serum free medium. The cells were incubated in CO2 incubator at 37°C 
for 6h and replaced with Ad-ZBP-89 infection for another 24h and 48h. 
Flow Diagram of APO-DIRECT Apoptosis Assay kit was then used for this 
assay on all tested cells as described in ‘Ch.2 Materials and method' 2.2.5. 
3.2.6.3. RT-PCR and Western blot analysis 
Untransfer control, pcDNA3.1 and pcDNA-Bak transfer groups were 
designed for transfection for Hep3B, PLC/PRF/5 and SK-Hep-1 cell lines. 
Gene transfer was conducted with Lipofectamine 2000，according to the 
suggestion of the manufacturer. After 6h of pcDNA-Bak transfection, MOI 
100 Ad-ZBP-89 was infected for another 24 and 48h for Bak mRNA and 
protein detection. Cellular Bak mRNA expression levels were assayed by 
RT-PCR. Cellular total RNA extraction was conducted with RNeasy® Mini 
Kit (QIAGEN GmbH, Hilden, Germany). After the reverse transcription 
reaction, PCR amplification reaction was conducted with Bak (400bp) and 
GAPDH (435bp) primers listed in Table 2.1. GAPDH served as an internal 
control for PCR. Amplification products were separated with 1% agarose 
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electrophoresis and observed under UV light. Cellular Bak protein 
expression levels were assayed via Western Blotting. The extraction, 
quantification and separation of proteins were conducted according to the 
above procedures. Blots were incubated sequentially with 5% non-fat dry 
milk, rabbit polyclonal anti-Bak antibody and mouse radish 
peroxidase-conjugated anti-rabbit immunoglobulin G, and evaluated using 
an ECL Western blotting kit. P-actin served as an internal control for the 
immunoblot. Protein band intensities were determined densitometrically 
using the computer imaging system. 
3.2.7. RT-PCR and Western blot analysis on tissues samples 
Twenty pairs of HCCs and adjacent nontumor counterparts were obtained at 
the time of surgical resection. Their protein and mRNA were extracted and 
prepared for use. Western blot analysis and RT-PCR was performed on these 
samples for Bak expression. 
3.2.8. Statistical Analysis 
Data analysis was performed using SPSS 10.0 statistical software. Data 
were expressed as mean 土 SD and for at least three separate determinations 
for each group. Differences between groups were examined for statistical 
significance using Student's t-test or one-way ANOVA followed by 
Student's t-test among groups. The difference was considered statistically 
significant if p<0.05. 
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3.3. Results 
3.3.1. ZBP-89 activates Bak-Iuciferase reporter gene 
To explore the mechanism of Bak gene activation by ZBP-89, we determined 
the effect of this transcription factor on the activity of Bak promoter 
-luciferase reporter genes. We constructed 10 Bak promoter-luciferase 
plasmids carrying sequential 5’ deletions of the Bak promoter: pGL-3-Bak 
-1965， -1745, -1529， -1280, -1109, -881， -706， -481， -287， -181. These 
plasmids carry the different lengths of the human Bak gene proximal to its 
AUG start codon (schematic representations of the Bak promoter deletion 
constructs are presented in Fig.3.1A). Each 4 tested cells were transiently 
transfected with 1.5|ig of individual Bak promoter luciferase construct or 
pGL3 control plasmids. After 6h, cells were infected with MOI 100 
Ad-ZBP-89 or without Ad-ZBP-89 for 16h and luciferase activities were 
measured. Relative luciferase units were determined and fold increase in 
activation was calculated to represent the results. The results (Fig.3.2) showed 
that ZBP-89 activated -706 and -481 Bak promoters by approximately 2.6 
folds in PLC/PRF/5 cells and 4 folds in SK-Hep-1 cells, but not in Hep3B and 
Chang cells. We also observed a major decrease in promoter gene activation 
in the case ofpGL3-Bak promoter -287 in PLC/PRF/5 and SK-Hep-1 cells, in 
which the level of the luciferase activity was slightly higher than that seen in 
the cells transfected with pGL3-basic plasmid alone (-0.5 fold in both 
PLC/PRF/5 and SK-Hep-1 cells). Plasmids carrying shorter Bak promoter 
fragments also showed a low basal level of activity, therefore localizing the 
protein-DNA binding site of ZBP-89 at a Bak promoter region between -706 
and -287, a 419bp region. Fig.3.4.1 showed the diagram for the 419bp 
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sequence of the putative ZBP-89-Bak binding area. 
A. Luciferase activity of fold change in Hep3B cells 
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C. Luciferase activity of fold change in SK-Hep-1 cells 
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D. Luciferase activity of fold change in Chang cells 
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Fig.3.2. Activation of the Bak-promoter luciferase gene by ZBP-89 in (A) 
Hep3B, (B) PLC/PRF/5, (C) SK-Hep-1 and (D) Chang cells. Equal amounts 
(1.5)ig) of pGL3-control plasmid or pGL3-Bak luciferase promoter plasmids 
which carry various 5' delection of pGL3-Bak promoter regions were used in 
transfection. The pGL3-control plasmid was used for efficient transfection. 
After 6h of transfection, the cells were then infected with MOI 100 
Ad-ZBP-89 for 24h. Cells were lysed for determination of relative firefly 
lucifease activity and fold activation (+ZBP-89/ -ZBP-89) was calculated. The 
results were obtained from 3 independent experiments, and the values are 
expressed as mean 土 SD (p<0.05). 
3.3.2. ZBP-89 activates a specific region of Bak-promoter gene 
Luciferase activity was further assayed on five ~100bp fragments, which 
shown as below, with -lObp overlap with each other. These five fragments 
spanned the total length of putative binding region (419bp) of Bak promoter 
for ZBP-89 in PLC/PRF/5 and SK-Hep-lcells. Diagram below explains how 
the five different fragments were organized. A series of DNA fragments 
generated by full-length Bak DNA sequence were amplified by PCR and 
cloned into pGL3-basic at Mull and Xhol sites. Sequencing of every 
pGL3-Bak plasmids was confirmed before cell transfection. Luciferase assay 
was then used to further localize the Bak-ZBP-89 binding site from the five 
shortened Bak promoter fragments in PLC/PRF/5 and SK-Hep-1 cells. The 
result showed that the DNA protein binding site seemed to locate between 
-527 to -338 (al89bp fragment) in both PCL/PRF/5 and SK-Hep-1 cells. 
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-706 u m i m -608 
-617 ^ m m -518 
-527 -428 
-437 m m m -338 
-347 m m - 2 8 7 
Fig.3.3A Diagram illustrated the five shortened putative Bak promoter 
fragments (lOObp) resulted from the luciferase assay. 
B. Luciferase activity of fold change in PLC/PRF/5 cells 
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C. Luciferase activity of fold change in SK-Hep-1 cells 
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Fig.3.3 Luciferase activity of fold change in the shortened Bak promoter 
fragments containing putative binding region for ZBP-89 in PLC/PRF/5 
cells (A) and SK-Hep-1 cells (B). Bak-promoter activity was analyzed in 
PLC/PRF/5 and SK-Hep-1 cells using a luciferase-based reporter-gene 
transactivation assay. Cells were transiently transfected with pGL3-Bak 
promoter or pGL3 basic plasmid or pGL3 control plasmid as the positive 
control of transfection efficiency and luciferase activity. After 6h treatment, 
cells were infected with Ad-ZBP-89 for another 24h before being collected 
for luciferase activity described in 3.2.2. Results (A) and (B) are shown as a 
fold change of the activity in PLC/PRF/5 and SK-Hep-1 cells transfected with 
five different sets of -lOObp putative Bak promoter. Results are obtained in 3 
independent experiments and values are shown as means 土 SD (error bars). 
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3.3.3. Localization of the ZBP-89 DNA-protein binding site within the 
Bak gene 
The putative binding region of ZBP-89 and Bak from the first luciferase result 
(highlight in Black) was shown below. Analysis of the 419bp nucleotide 
sequence of the below region using TFSEARCH algorithms and a search 
program (http://motif.genome.ad.ip/) revealed the presence of putative 
binding sites for a restricted number of DNA-binding proteins. The analysis 
suggested that the sequence between -435 and -426, a lObp fragment 
(highlight in Red), might be the putative binding site for ZBP-89. This 
theoretical responding region is within the fragment regions showing 
increased luciferase activity (the second assay) in PLC/PRF/5 and SK-Hep-1 
cells. In order to test whether the candidate protein ZBP-89 could bind to the 
putative sites, we randomly choose three pairs of Bak complementary 
oligonucleotides (highlight in Blue), each with 50bp that surrounded the 
region of the putative binding site, for the electrophoresis mobility shift essay 
(EMSA). Fig.3.4.1 shown below illustrated the general position of the Bak 
binding regions. 
-707 agtaaggtga gggtgaaact tctcttttaa aaaaatgttt acatagaaac aaactaaatg 
-647 gacaaaatgg atataaacaa aaatgttatc ggtggttatt tttgggcagt agaattatag 
-587 gtttttaatt tcttttgctt atttatagtt tcaaaaattt tcaattttaa tataaattaa 
-527 tgtgctctat ttatagagac.aatacatgaa atatacttaa taaaaattca aatgttatag 
-467 aactgaaaaa gatgaaaagt aaaaacaacc tattccccag aggtagccac tgtccatagt 
-407 ttctatttta gattctttcc tttatacaag attattatag cttctatttt ttggtgtatg 
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Fig.3.4.1 Diagrams illustrated the part of the putative binding sequence from 
the human Bak gene. Black colour indicated the ZBP-89 and Bak responding 
region, -706 to -287, (419bp) from the first luciferase activity assay in 
SK-Hep-1 and PLC/PRF/5 cells. Blue colour indicated the shortened putative 
DNA-protein binding area, -507 to -357, (150bp), which was designed 
according to the second luciferase result and the search programme. The 
EMSA was finally carried out in 50bp genes for each reaction set, trying to 
confirm that the binding site of ZBP-89 and Bak (Red colour) is between -457 
to -407. 
EMSA was used to determine whether ZBP-89 protein isolated from 
PLC/PRF/5 and SK-Hep-1 nuclear extract can bind the specific site of the 
Bak promoter. For this assay, we labelled double-stranded DNA with biotin. 3 
pairs of complementary oligoes (Table 3.5) were separately end-labeled 
before application for the assay. The results (Fig.3.4.2) showed a clear shifted 
complex in one of the three Bak promoter genes, indicating that the nuclear 
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protein isolated from Ad-ZBP-89-infected cells can bind this specific 50bp of 
the Bak promoter. When 100-fold excess of unlabeled target oligonucleotides 
DNA was added respectively in each set of reaction, competition occurred 
between the biotin 3，end labelled DNA and the excess non-labeled DNA 
which it effectively blocked the band shift, demonstrating the existence of 
protein:DNA interaction between ZBP-89 and Bak and confirming the 
specificity of binding. These results show that both PLC/PRF/5 and 
SK-Hep-1 cells with ZBP-89 overexpression is capable of specifically 
binding to the putative Bak-ZBP-89 binding site. 
A. EMS A binding reaction in PLC/PRF/5 cells 
. (a) (b) (c) control 
1 2 3 1 2 3 1 2 3 1 2 3 
• 
89 
B. EMS A binding reaction in SK-Hep-1 cells 
(a) (b) (c) control 
1 2 3 1 2 3 1 2 3 1 2 3 
^ H H H H H H I H E 
Fig. 3.4.2 EMS A analysis of binding of ZBP-89 to its response elements in 
the Bak promoter. The binding reactions included a complete set of three 
reactions each time. The reaction contained the biotin end-labelled target 
DNA only, and therefore no shift is observed. The finding demonstrated the 
position of an unshifted probe band. The contained the nuclear protein 
extract in addition with the biotin end-labelled target DNA. The shift was 
detected by comparison to the band position in the reaction no. 1，indicating 
that the target protein (ZBP-89) from the nuclear extract binds to its 
corresponding DNA labelled with biotin. The was the mixture of 
unlabeled target DNA, nuclear protein extract and the biotin end-labelled 
DNA. It demonstrates that the signal shift observed in the reaction no. 2 can 
be prevented by excess non-labelled DNA in a competitive way. The 
expected result for the control Epstein-Barr Nuclear Antigen (EBNA) 
System is showed. Sequences of the Bak oligonucleotides used in EMS A are 
listed in Table 3.5. Three pairs of 50bp double stranded oligonucleotides 
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were 3'end labelled with biotin and used as a probe in EMSA with nuclear 
extract proteins isolated from PLC/PRF/5 and SK-Hep-1 cells. (A) 
representative results of the nuclear protein from PLC/PRF/5 and (B) 
representative results of the nuclear protein from SK-Hep-1 cells, (a) -507 to 
458 DNA fragment of the Bak promoter, (b) -457 to -408 and (c) -407 to 
-357. 
3.3.4. The overexpression of Bak and Ad-ZBP-89 infection in 
combination greatly increase the apoptosis in HCC cells 
Hep3B (A), PLC/PRF/5 (B), SK-Hep-1 (C) and Chang (D) cells were 
transfected with pcDNA Bak or pcDNA empty vector and then treated with 
or without MOI 100 Ad-ZBP-89 for 24 or 48 hours. At the end of the 
treatment, apoptosis was detected by TUNEL assay. The results (Fig.3.5) 
showed that the proportion of apoptosis in cells treated by ZBP-89 plus 
pcDNA-Bak was significantly higher than those treated by either agent 
alone.. The percentage of apoptosis induced by either Ad-ZBP-89 infection 
or Bak overexpression alone was quite similar in both PLC/PRF/5 and 
SK-Hep-1 cells, ranging from 22 to 27% in cells treated for 24h, and 34 
to43% in cells treated for 48h. The combined treatment with Bak 
overexpression and ZBP-89 infection for 24h also produced a similar 
percentage of apoptotic cells in both PLC/PRF/5 (31.7%) and SK-Hep-1 
(34.8%) cells. The combined treatment for 48h increased the percentage of 
apoptosis to an approximately 1.3 fold in both PLC/PRF/5 and SK-Hep-1 
cells compared with the result of 24h treatment. The percentage of 
apoptosis in Hep3B appeared to be the lowest among the HCC cells tested. 
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The diagrams showed the representative result of TUNEL assay measured 
by flow cytometry. If the peak shifted more to the right, it indicates that 
more number of cells die in apoptosis. The table below showed each 
diagram detailed the percentage of apoptosis in cells treated by different 
protocols. In general, the results indicated that a significant increase of 
apoptosis in HCC cells treated by ZBP-89 infection and Bak overexpression. 
A. Apoptosis detected in Hep3B cells 
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treatment (h) 
Ad-ZBP-89 (-) and 3.5 ± 1 . 7 0 
pcDNA3.1 empty plasmid 3.7 ± 2.1 24 
^ 3.1 土 2 . 5 4 8 
MOI 100 Ad-ZBP-89 (+) and 12.5 土 1.6 ^ 
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B. Apoptosis detected in PLC/PRF/5 cells 
control h 
I • j n i i I ^ 
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treatment (h) 
Ad-ZBP-89 (-) and 2.5 土 2.4 0 
pcDNA3.1 empty plasmid 3.3 ± 3.0 24 
3 . 0 土 1.8 4 8 
MOI 100 Ad-ZBP-89 (+) and ** 22.5 土 2.3 24 
pcDNA3.1 empty plasmid * 36.4 ± 3.6 4S 
Ad-ZBP-89 (-) and 24.7 ± 1 . 4 24 
pcDNA_Bak * 34.6 ± 2.2 4S 
Ad-ZBP-89 (+) and ** 31.7 土 0.8 ^ 
pcDNA—Bak * 42.3 土 1.6 
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B. Apoptosis detected in PLC/PRF/5 cells 
control 
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Treatment Apoptosis cells (%) Period of the 
treatment (h) 
Ad-ZBP-89 (-) and 2.1 ± 2.0 0 
pcDNA3.1 empty plasmid 2.6 土 1.7 24 
2.2 土 2.2 48 
MOI 100 Ad-ZBP-89 (+) and * 27.5 土 2.6 24 
pcDNA3.1 empty plasmid 43.4 ± 2.3 48 
Ad-ZBP-89 (-) and * 25.3 土 2.8 24 
pcDNA_Bak * 38.6 土 3.2 48 
Ad-ZBP-89 (+) and * 34.8 ± 1.5 24 
pcDNA—Bak ** 47.4 土 2.7 48 
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treatment (h) 
Ad-ZBP-89 (-) and 2.8 ± 1.5 0 
pcDNA3.1 empty plasmid 3.1 ± 2.6 24 
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MOI 100 Ad-ZBP-89 (+) and * 23.8 ± 1 . 8 24 
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pcDNA_Bak 38.4 土 2.7 48 
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Fig.3.5. The apoptosis induced by Bak overexpression and Ad-ZBP-89 
infection in HCC cells. The % of apoptosis induced by different treatments 
detailed in above figures and tables was detected by TUNEL assay using 
flow cytometry as described in the section of 2.2.5，Chapter 2 'Materials and 
methods' The percentage of apoptotic cells is shown for Hep3B cells (A), 
PLC/PRF/5 cells (B), SK-Hep-1 cells and Chang cells (D). The proportion 
of the apoptotic cells was determined relative to Oh cells at the absence of 
Ad-ZBP-89 and pcDNA-Bak. Data are represented as the mean 土 SD of 
three independent experiments with similar results. A significant difference 
in cellular apoptosis was observed between Bak overexpression, Ad-ZBP-89 
and the combined effect of Bak and Ad-ZBP-89 in Hep3B, PLC/PRF/5 and 
SK-Hep-1 cells at indicated time points but not in Chang cells (*p<0.05 and 
**p<0.01, Student's t test). 
3.3.5. The expression of Bcl-2 family proteins in HCC cells transfected 
by pcDNA-Bak and/or infected by Ad-ZBP-89 
Comparing with the control, the expression levels of pro-apoptotic Bak were 
increased in all cells transfected with pcDNA-Bak. The increase of Bak 
level in Ad-ZBP-89-infected cells was found similar to that transfected with 
pcDNA-Bak. In Hep3B, PLC/PRF/5 and SK-Hep-1 cells, the Bak level of 
the combined treatment at 24 and 48h were significantly higher than either 
one of the treatments. The Bcl-2 expression was too weak to detect in all 
cells. 
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A. Bak protein expression in Hep3B cells 
Ad-ZBP-89 - 24h 48h - - -
pcDNA-Bak 24h 48h - -
pcDNA-Bak+ 
Ad-ZBP-89 - - - - 24h 48h 
Bak 26kD 
Actin — I ^ ^ ^ ^ M g a ^ J H 
B. Bak expression in PLC/PRF/5 cells 
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C. Bak expression in SK-Hep-1 cells 
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Fig.3.6 Expression of Bak in Hep3B (A), PLC/PRF/5 (B) and SK-Hep-1 (C) 
cells treated with either Ad-ZBP-89 infection or pcDNA-Bak transfection, 
or both in combination. The cells were transfected with pcDNA-Bak for 
6h, and then treated with or without Ad-ZBP-89 (MOI 100) for 24 or 48h. 
Whole cell lysates were prepared and Western blotting was used to measure 
the expression of Bak. The level of actin was detected，which was used as a 
control to verify the equal loading. The density of targeted protein bands 
was determined in the cells treated for 24 and 48h (D). The results are 
representative of three independent experiments and the statistically 
significant differences from untreated cells were labelled as * p<0.05 and * 
*p<0.01. 
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3.3.6. Expression of Bak in human HCC tissues 
Expression of Bak was examined by Western blot analysis in 20 pairs of 
surgically resected human HCC tissues and their adjacent non-tumor tissues. 
In 5 of 20 cases, it showed no Bak difference between tumor and non-tumor 
tissues. Tissue samples of 371 and 394 are reported to extract from 
post-chemotherapy HCC tissues, whereas sample 396 is the tissue from 
reoccurrence HCC. Unlike the other pairs of HCC tissues, no obvious 
changes in Bak expression were observed in these samples. In the rest of 13 
samples, the expression of Bak was lower in the tumor tissue samples than 
that in the non-tumor samples. 
369 370 371 372 373 
B- md^mnm --
Actin 
376 377 378 381 382 
N T N T N T N T N T 
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383 384 385 387 389 
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391 392 394 395 396 
N T N T N T N T N T 
Actin I B r o K ^ P g g K a i l 43kD 
Fig.3.7 Bak expression in human HCC liver tissue samples. Expression of 
Bak was assessed by Western blot analysis in 20 pairs of HCC (T), and their 
adjacent non-tumor liver counterparts (N). The level of actin was served as a 
control for sample loading. 
3.4. Discussion 
ZBP-89 expression has been associated with apoptosis in response to a 
number of stress stimuli, including anticancer agents (Bai L, Yoon S O et al; 
2003), retinoic acid (Bai L, Logsdon C et al; 2002). In addition to its 
function as a transcription factor (Bai L, Merchant JL; 2000，2003, Park H, 
Shelley C S et al; 2003), ZBP-89 has been shown to mediate apoptosis 
through Bcl-2 family member pathway. However, no study has sought to 
establish a direct link between ZBP-89-me(liated apoptosis and Bak 
expression. Here, we demonstrated that ZBP-89 could promote apoptosis by 
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up-regulating Bak independent of the p53 status. In previous section, we 
have described the employment of siRNA to knock down endogenous 
ZBP-89 expression in order to assess its effect on Bak expression (Fig.2.6). 
ZBP-89 silencing resulted in a marked decrease in Bak levels, establishing 
that Bak is a ZBP-89 target gene. To further explore the mechanism of Bak 
gene activation by ZBP-89, the transient transfection was herein employed 
to examine the molecular mechanisms by which ZBP-89 transcriptionally 
activates the Bak gene. We found that the approximate two to four folds of 
increase in the activation of the Bak gene were mediated by a biologically 
functional DNA-protein binding site located between -457 and -407. The 
computer programme suggests that this region contains a major response 
element, CCCCAGA, which is very likely to be the binding sequence for 
ZBP-89 (Fig.3.4.1). The putative binding site was further shortened and 
proved by our EMS A experiments. For PLC/PRF/5 and SK-Hep-1 cells, 
EMSA demonstrated that the nuclear protein from HCC cells was able to 
bind to this specific promoter region of Bak gene. The results suggested that 
changes in Bak promoter activity may be critically involved in 
ZBP-89-induced apoptosis of HCC cells, indicating that ZBP-89 may be a 
novel therapeutic target in HCC. 
Apoptosis induced by a variety of cellular stresses is mediated at least in 
part by the tumor suppressor gene p53 (Graeber TG, Osmanian C et al; 1996， 
Gottlieb E, Haffner R et at; 1994，Lowe SW, Schmitt EM; 1993). Although 
HCC may acquire resistance to apoptosis by inactivating the p53 gene 
function, mutations or deletion of p53 are not generally found until the late 
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stages of HCC (Oda T, Tsuda H et al; 1992). In this study, we have found 
that Bak is expressed in both wild-type p53 positive (SK-Hep-1) and p53 
negative hepatoma cell lines (Hep3B, PCI7PRF/5) (Fig.2.1). Most 
significantly, Hep3B, which was resistant to p53-activated apoptosis, 
experienced apoptosis when the level of Bak was up-regulated by 
Ad-ZBP-89, suggesting that p53 was not required in the apoptosis induced 
by Ad-ZBP-89. Therefore, ZBP-89 induced Bak can function to induce 
apoptosis in p53-resistant HCC cells. Although the balance between 
pro-apoptotic and anti-apoptotic Bcl-2 family proteins is important for the 
regulation of apoptosis (Adams JM, Cory S; 1998), proapoptotic proteins 
including Bax, Bad and Bid were expressed in HCC tissues at the levels 
similar to those in adjacent nontumor or normal liver tissues (Maryvonne 
Daveau, Michel Scotte et al; 2003, Tetsuo Takehara et al; 2003). Therefore, 
dysregulated expression of Bak found in this tested liver tissues may play an 
important role in the regulation of apoptosis in HCC. Bak was also 
discovered to express or highly up-regulate in human liver cells by the effect 
of anticancer agents, like Taxol (Cheng SC et al; 2001) or transcription 
factor, HBx (Han J et al; 2000). We propose that the expression of Bak in 
HCCs may function as a pivotal apoptosis-inducer to maintain the 
homeostasis of hepatocytes. Its deficiency is a factor that promotes the 
development of HCC. 
The Bak gene encodes a 26KD protein and is a pro-apoptotic member of the 
Bcl-2 family. Its expression is up-regulated through a DNA-binding 
response element located within the Bak promoter. Induction of Bak has 
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been observed during p53-mediated cell death in a number of cell systems. 
The ratio of Bak: Bcl-2 has been linked to a rheostat that determines the 
survival or death of the cells (Amotz Nechushtan et al; 2001). The relative 
dominancy of Bak for Bcl-2 may play an important role in apoptosis in HCC 
cells containing functional p53 (Simone Fulda, Klaus-Michael Debatin; 
2004). Following in my study, over-expression of Bak using Bak gene 
transfection is applied to observe the cell growth arrest in HCC cells and to 
see whether it is p53 or other anti-apoptotic proteins independent.. It appears 
that the combined effect of Ad-ZBP-89 infection and pcDNA-Bak 
transfection can markedly increase the Bak expression and greatly induce 
apoptosis, although Hep3B cells with deletion in p53 were the least response 
to the treatment (Fig 3.5 and 3.6). PLC/PRF/5 and SK-Hep-1 cells were 
shown to have nearly the same trend on the combined treatment. These 
findings suggested that the induction of apoptosis by both of the agents is 
not determined by the p53 state. The cell death induced by administration of 
Ad-ZBP-89 and over-expression of Bak was confirmed to be apoptotic in 
several ways. First, the HCC cells showed a significant increase in apoptosis 
after the treatment with ZBP-89 infection and Bak overexpression in 
combination. Second, Bak expression detected by Western blot is increased, 
which induces cytochrome c release in all cells tested. These results indicate 
that ZBP-89-induced mitochondria apoptosis and anti-cellular proliferation 
are accomplished through the over-expression of Bak, leading to apoptosis 
of HCC cells. Bak is closely connected with cytochrome c which is usually 
activated to induce the downstream effector caspases like caspase 3，6 and 7. 
Therefore, up-regulation of Bak may accumulate cytochrome c in the 
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cytosolic fraction of the cells upon Ad-ZBP-89 treatment observed in my 
study (Fig.2.5), suggesting that the release of mitochondrial cytochrome c is 
blocked by endogenously expressed Bcl-2 in HCC cells. Our results also 
suggest that over-expressing of Bak though pcDNA一3.1 plasmid 
transfection can promote the apoptotic in HCC cells, as the death signal can 
be amplified within the cells after an initial step is promoted. This effect is 
critically important, since one of the most difficult problems in the current 
gene therapy is low delivery efficiency of therapeutic genes into target 
cancer cells. Therefore, gene transfection of Bak can be a promising way to 
induce apoptosis in HCC. Importantly, ZBP-89-mediated apoptosis can 
occur in both p53-sensitve and resistant cells. We have also demonstrated 
that the expression of Bak was reduced in a subset of human HCC tissues as 
well as in human hepatoma cell lines (Fig.3.7). Cell culture experiments 
show that the level of Bak can be significantly up-regulated by Ad-ZBP-89, 
which is followed by the occurrence of apoptosis in HCC cells regardless of 
the status of p53 in these cells. 
These data, therefore, indicate that the ZBP-89-mediated apoptosis is via the 
induction of pro-apoptotic Bak and this process is independent of the status 
of pro-apoptotic p53. However, this may involve the anti-apoptotic Bcl-2 
because increase of Bcl-2 expression was observed when ZBP-89 was 
blocked in the siRNA transfected HCC cells, although infection of 
Ad-ZBP-89 did not result in an reduction of Bcl-2 here. Further 
investigation of the relation between ZBP-89 and Bcl-2 may provide another 
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4.1. Conclusion 
Therapy resistance is the common clinical problem in patients suffering with 
hepatocellular carcinoma. This is in part due to a high expression rate of 
drug resistance genes, including p-glycopreotein, glutathione-s-transferase, 
heat shock proteins and mutations in p53. The aim of the present study "was 
to investigate whether ZBP-can induce apoptosis of HCC cells and the 
mechanism responsible for ZBP-89-mediated apoptosis in HCC cells. The 
results of this study show that both Bak and ZBP-89 are slightly expressed 
in human HCC cell lines (Fig.2.1), and the enhanced expression of Bak 
either by ZBP-89 adenovirus infection or gene transfection inhibits cell 
proliferation and induces apoptosis in HCC cells. Our data suggest that 
ZBP-89 is able to induce apoptosis of HCC and that ZBP-89-mediated 
apoptosis mainly results from the increase of Bak expression in HCC cells. 
Therefore, ZBP-89 appears to be a promising target for with the treatment 
of HCC. 
Apotosis is a common property of multicellular organisms. It eliminates 
unwanted and potentially harmful cells (Krammer PH; 2000). Defects in 
apoptosis signalling contribute to tumorigenesis and resistance to 
chemotherapy of HCC cells. These defects include instabilization of 
mitochondrial integrity and alterations in survival signalling and death 
receptor signalling (Schulze-Bergkamen H et al; 2004). They are the key 
mechanism for both the survival of a malignant cell and its resistance to 
chemotherapy (Thomas MB & Zhu AX; 2005). Bcl-2 family, is a well 
established family of proteins, and it has a significant impact on 
mitochondrial integrity by influencing the mitochondrial outer membrane 
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permeabilization (MOMP). Anti-apoptotic members, such as Bcl-2, Bcl-xL 
and Mcl-l, stablilize mitochondria and inhibit MOMP by interacting with 
pro-apoptotic BH3-only family members, such as Bid, Bim, PUMA and 
NOXA, thus preventing the activation of Bak, Bax (Garrido C & Kroemer G; 
2004). There are growing studies about the role of Bak in the apoptosis of 
HCC cells (Rousseau B et al; 2007, Cheng SC et al; 2001, Han J et al; 2000). 
The major finding of this study is that Bak expression is enhanced in HCC 
cells upon treatment with the transcription factor, ZBP-89, leading to a 
marked increase of apoptosis in HCC cells. The mechanism responsible for 
the ZBP-89-mdiated Bak up-regulation was also explored. Computer 
program analysis revealed that Bak promoter contained a putative ZBP-89 
binding site and this was experimentally confirmed using promoter report 
activity assay and EMSA. 
In mammals ZBP-89 is expressed in many tissues in addition to liver 
(Merchant et al; 1996，Passantino et al; 1998) and is expressed during both 
fetal and postnatal stages (Merchant et at; 1996). This ubiquitous and 
development mental stage-independent expression argues against a decisive 
role of ZBP-89 in postnatal liver-specific expression of the Bak mRNA 
(Lucy et al; 1998). Increasing evidence indicates that tissue-specific and 
developmental regulation of gene expression is the result of collaborative 
actions of many tissue-enriched and many ubiquitously and constitutively 
expressed transcription factors (Brivanlou and Darnell, 2002). ZBP-89 is 
likely to be one of the ubiquitous transcription factors that collaborate with 
liver-enriched transcription factors such as HNF-4x and HNF-4y, for which 
the Bak promoter contains a binding site, thereby facilitating Bak mRNA 
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expression in the HCC cell. 
The pro-apoptotic Bak gene is located on chromosome 6 and shares 
homology with the entire Bcl-2 family, including the anti-apoptotic and 
pro-apoptotic members (Herberg JA, Phillips S et al; 1998). In fact, the 
family members interact through highly conserved areas of Bcl-2 homology 
(BHl, 2 and 3) that allow hetero- and homodimerization and consequently it 
regulated apoptosis (Manion MK, Hockenbery DM; 2003). In the case of 
Bax, this scheme has been well worked out in a rheostat model in which 
excess pro-apoptotic Bax suppresses Bcl-2 and induces apoptosis via 
cytochrome c (Liu J, Yin S et al; 2004). Less is known about Bak, but there 
is evidence that Bak can form heterogenous dimmers with Bcl-2 or Bcl-xL 
to inhibit their anti-apoptotic function. Bak also plays a role in facilitating 
apoptosis induced by other pro-apoptotic Bcl-2 proteins such as Bax and Bid 
since the presence of Bak is required for mitochondria to release cytochrome 
c whereas the deficiency in Bak can lead to the arrest in cytochrome c 
release (Wang GQ, Gastman BR et al; 2001), thus enabling cells to survive. 
For example, suboptimal dose of recombinant Bak can reverse the resistance 
of the mitochondria to release of cytochrome c in response to Bax, 
suggesting that there is a synergistic activity between Bak and Bax 
(Degenhardt K, Sundararajan R et al; 2002). Bak-deficient Jurkat cells have 
also been shown to be resistant to tBid induction of cytochrome c release 
(Wang GQ, Wieckowski E; 2001)，suggesting that in these leukemic cells, 
Bak is involved in mitochondria cytochrome c release induced by either tBid. 
Current evidence indicated that deficiency of Bak expression is closely 
correlated with occurrence and development of tumors (Rosen K, Rak J et al; 
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1998). Kondo et al found that Bak expression were negatively correlated 
with the pathological stages and clinical phases of gastric cancer (Kondo S, 
Shinomura Y et al, 2000). Many kinds of tumor therapeutic drugs, such as 
Taxol, perillyl alcohol and gama-interferon, function through up-regulating 
Bak expression (Cheng SC et al; 2001，Ahn EY, Pan G et al; 2002). 
Meanwhile, Pataer reported that adenoviral-mediated overexpression of Bak 
could induce obvious apoptosis in lung and breast cancer cells, suggesting 
that the introduction of Bak may serve as a novel therapeutic strategy for 
these cancers (Pearson AS, Spitz FR et al; 2000). 
Since chemotherapeutic treatment for HCC patients is often ineffective 
(Schuchmann M et al; 2004), elevation of pro-apoptotic Bcl-2 protein levels 
by gene transfer to accelerate apoptosis has been tested in different models. 
This study has shown that ZBP-89 significantly up-regulate Bak and 
induced apoptosis of HCC cells. To assess if pro-apoptotic Bak is a feasible 
target in the induction of apoptosis of HCC cells, we analyzed whether the 
resistance to apoptosis in HCC cells could be increased if Bak expression 
was silenced. To this end, Bak siRNA was used to block the expression of 
Bak. The result showed that Bak siRNA significantly reduced not only the 
non-stimulated HCC cells to express Bak but also Ad-ZBP-89-mediated Bak 
expression in all tested cells (Hep3B’ PLC/PRF/5, SK-Hep-1 and Chang). 
While Bak was down-regulated, the apoptosis of these cells also remained 
very low. In the Bak siRNA-treated cells, the percentage of apoptosis 
induced by Ad-ZBP-89 was reduced 50% or even less, compared with the 
cells without Bak siRNA treatment. The importance of Bak in apoptosis of 
HCC cells was further confirmed using ZBP-89 siRNA. When the cells 
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were treated with ZBP-89 siRNA, the level of Bak was markedly decreased 
and the cells were less likely to be apoptotic. The findings confirm that the 
block of Bak is therapeutically significant in HCC cells. It also further 
supports the Bak is a major target in ZBP-89-mediated apoptosis of HCC 
cells. 
Transient transfections were employed to examine the molecular 
mechanisms by which ZBP-89 transcriptionally activates the Bak gene. We 
found that the approximate two- to fourfold increase of the Bak report 
activity was mediated by a biologically functional ZBP-89-Bak binding site: 
5'-TCCCCAGA-3' located between -437 and -427 in the SK-Hep-1 and 
PLC/PRF/5 cells (Fig.3.3). Remarkably through checking the sequence 
using an online search programme, this response element is proved to be the 
putative binding site for the zinc finger protein. The result of EMSA also 
demonstrated that the purified nuclear extract from HCC cells was able to 
bind to the specific Bak promoter binding site. It will be of interest in the 
future to examine in detail how ZBP-89 protein interaction with Bak 
promoter, particularly the potential binding site region identified. The role 
that ZBP-89 plays in hepatoma biology remains somewhat unclear. For 
example, ZBP-89 appears to play a role in the growth arrest of the gastric 
adenocarcinoma AGS cell line, and yet it has been shown to be 
overexpressed in gastric cancers. The fact that ZBP-89 binds to the p21 
promoter and interacts with p53 strongly suggests that its major function is 
related to the inhibition of cell proliferation (Bai L, Logsdon C et at; 2002, 
Bai L，Yoon So et al; 2004). 
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Recent studies have demonstrated that p53 has a direct signalling role at 
mitochondria to induce apoptosis. The tumor suppressor activity of the p53 
protein has been explained by its ability to induce apoptosis in response to a 
variety of cellular stresses (Schuler M & Green D R; 2001，Vousden K H & 
Lu X; 2002). A fraction of stress-activated p53 translocates to mitochondria 
after an apoptotic stimulus, but not during p53-dependent growth arrest 
(Marchenko N D et al; 2000，Mihara M et al; 2003), although the 
mechanisms involved are not completely understood. Thus, understanding 
the mechanism by which p53 functions in the execution of cell death 
pathways is of considerable importance in cancer biology. Here we tested 
apoptosis induced by Bak-in HCC cell lines with different p53 status. After 
cells were infected with Ad-ZBP-89, the level of Bak and the apoptosis in 
the cells containing either wild type p53 (SK-Hep-1) or mutant p53 
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(PLC/PRF/5) was significantly increased in the cells containing either wild 
type p53 (SK-Hep-1) or mutant p53 (PLC/PRF/5).Although Hep3B cells, 
which has a deleted p53 gene, showed a slow response in increasing Bak 
expression and the lowest apoptotic rate among the HCC tested cells after 
infection of ZBP-89, this also suggested that the cell death in Hep3B cell is 
partly due to ZBP-89-mediated apoptosis. However it may not mainly 
through a Bak-related mitochondria pathway like the other HCC cells. This 
explained that ZBP-89-induced apoptosis was via a p53-independent 
pathway although other studies support a direct mitochondrial role for p53 
in apoptosis induction. Since, the effect of ZBP-89 shown to be adding on 
both of the wild type and the mutant p53 gene in order to up-regulate the 
activity of Bak, a downstream pro-apoptotic death effector, to induce 
apoptosis, studies on the p53 independent mechanism of ZBP-89 or the 
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relative contribution of the p53-mediated death in other cancers remain to be 
assessed. In vivo, it has been shown that a well-characterized p53 mutant 
lacking transcriptional function is defective at apoptosis induction in mice 
(Jimenez G S et al; 2000), which studies have shown p53 is important for 
mitochondrial localization (Dumont P, Leu J I et al; 2003). Further 
assessment of the relationship between ZBP-89 and p53 mutants inducing 
Bak-mediated apoptosis is warranted. 
In summary, the present studies have shown that Bak is one of the target 
genes for the ubiquitously expressed Kruppel-like zinc finger transcription 
factor ZBP-89. Given Bak is an important apoptotic factor for HCC, its 
expression is enhanced in HCC cell lines as well as in human HCC tissue 
(your results showed that Bak was reduced in most HCC tumor samples). 
Enhanced expression of ZBP-89 induces apoptosis in HCC cells. It is clear 
that ZBP-89 transcription factor is involved in the regulation of the other 
genes, and some of these genes are likely to govern Bcl-2 family activation 
or repression. Studies using animal model systems will be needed to further 
delineate the physiology role for ZBP-89 in regard to the Bak gene. The 
combination of gene therapy with existing clinical regimens such as 
chemotherapy and radiotherapy is likely to be more effective than separate 
approach alone. Studies have shown that the combination of adenovirus 
mediated gene with some common anti-tumor agents, like Dox, 5-FU or 
TNF-alpha, can significantly accelerate the virus-induced cytotoxcity, and 
such a therapeutical approach may also apply to ZBP-89.1 It is important to 
note the antitumor effect of ZBP-89 can be p53-independent. Thus,the 
application of ZBP-89 therapy may particularly useful for p53- resistant 
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HCC. 
4.2. Future Perspectives 
Recent studies strongly indicate that ZBP-89 plays a primary role in the 
regulation of epithelial cell growth. p53 is one of several key mediators of 
ZBP-89 action. Our finding has shown that ZBP-89 can inhibit liver cancer 
cell growth in a p53-dependent apoptotic pathway, indicating that it may be 
very useful in the liver cancer treatment. However, at present our findings 
are all obtained in vitro experimental models, which may not be the same as 
in vivo. Therefore, it will be important to confirm the result in in vivo 
models of liver cancer, particularly the model that is involved in different 
p53 status. In addition, a number of identified genes are known to target 
ZBP-89 protein in regulating cell growth. Therefore, it may help to screen 
these available genes to see how ZBP-89 is targted and whether there are 
alternative ways to regulate ZBP-89 in HCC cells. 
Clearly, our understanding of the biological functions of ZBP-89 is still 
incomplete and more studies are required. In order to have a comprehensive 
understanding of ZBP-89, identification of additional target genes will first 
help us to understand down-stream signalling pathways regulated by 
ZBP-89. Secondly, how ZBP-89 is expressed and transcriptionally activated 
during cellular proliferation, differentiation and transformation needs to be 
clarified. Even though many questions still remain unanswered, yet to 
discover an efficient therapy for liver cancer is important as there are 
currently no accepted adjuvant or palliative treatment modalities that have 
been conclusively shown to prolong survival in liver cancer. 
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